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Shiga-toxigenic Escherichia coli (STEC) and enteropathogenic E. coli (EPEC) are 
recognised to be significant contributors to intestinal and extra-intestinal disease and 
infantile diarrhoea worldwide. In New Zealand, STEC serotype O157:H7 is a notifiable 
pathogen. The routine use of sorbitol MacConkey (SMAC)-based agar to detect O157:H7 
fails to detect many potentially pathogenic non-O157 E. coli serogroups and EPEC is not 
currently under surveillance. As a result, the contribution of these pathogens to diarrhoeal 
disease is likely to be underrepresented in governmental surveillance reports. The intent 
of this project was to develop a multiplex qRT-PCR TaqMan assay suitable for the 
detection of STEC (stx1 and stx2) and EPEC (eaeA/intimin) marker genes, and to use 
this assay to survey diarrhoeic stool samples sourced from Dunedin Hospital. 
Prevalences of 1.53% and 4.41% (95% CI) were found for STEC and EPEC respectively, 
with 75% of stx+ samples possessing STEC belonging to serogroups other than O157. A 
trend towards an increased rate of STEC infection amongst samples also tested for 
Helicobacter pylori was also noted, indicating possible confusion of symptoms by 
clinicians. The project also tested a number of DNA extraction methods and pre-
enrichments to further adapt the assay to high-throughput diagnostic practice. The 
inexpensive Chelex-100 resin performed satisfactorily when compared with phenol-
chloroform and PrepMan Ultra methods. Trypticase soy broth was found to offer the 
most consistent pre-enrichment for STEC compared to other commonly used non-
selective liquid culture media. A 3 hour pre-enrichment of spiked faecal samples was 
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1.1 General Introduction 
Shiga-toxigenic Escherichia coli (STEC) are a toxin-producing subset of the normally 
commensal enteric bacterium E. coli and are recognised to be a significant contributor to 
diarrhoeal disease worldwide. In the United States, STEC are considered among the most 
prolific foodborne pathogens (1), estimated to be responsible for at least 100,000 
episodes of illness, 3,000 hospitalisations and 90 deaths annually (2, 3) at an estimated 
cost (as of 2009) of $478 million dollars (4). Much of the epidemiological and diagnostic 
efforts regarding STEC revolve around strains of the E. coli serotype O157:H7, known 
to be the serotype most commonly associated with progression to severe forms of 
gastrointestinal disease, such as haemorrhagic colitis (HC), and extra-intestinal disease, 
such as haemolytic uraemic syndrome (HUS) (5, 6). 
In recent years, international researchers and surveillance networks have noted increases 
in the number of cases of diarrhoea and more severe symptoms caused by STEC 
belonging to serogroups other than O157 (collectively referred to as ‘non-O157’ STEC) 
(7). Non-O157 STEC are recognised to contribute to a significant proportion of STEC-
related illness in first world countries (8), with some strains considered to have a 
pathogenic potential comparable to that of O157:H7 (8, 9). Much of the disease burden 
presented by non-O157 STEC remains under-reported in many countries (10, 11), mainly 
due to limitations in popular diagnostic techniques to detect these serogroups (2, 12). 
E. coli O157:H7 related disease is notifiable in New Zealand, and national data 
accumulated since the first case of O157:H7 infection in 1993 indicates that the incidence 
of all reported STEC has been steadily increasing in ensuing years (13, 14). The isolation 
and subsequent reporting of E. coli O157:H7 by diagnostic laboratories is typically based 
upon plate culturing of faecal samples on Sorbitol MacConkey Agar (SMAC), which 
provides limited information on the presence of non-O157 STEC. The intent of this 
project was to design a practicable multiplex qPCR test procedure that could be used to 
identify both non-O157 and O157 STEC, and to use this to determine the prevalence of 
these bacteria within diarrhoeal stool samples sourced from Dunedin Hospital. A 
secondary objective was to investigate the incidence of the E. coli outer membrane 
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protein intimin as a marker of the Locus of Enterocyte Effacement (LEE) pathogenicity 
island, which is a key virulence factor in infections of both STEC and enteropathogenic 
E. coli (EPEC). 
1.2 Shiga-toxigenic Escherichia coli 
STEC, also referred to as Vero-cytotoxigenic E. coli (VTEC) or Shiga-like toxigenic E. 
coli (SLTEC), are one of several gastrointestinal pathotypes of E. coli, a Gram-negative 
facultatively anaerobic bacterium that inhabits the mucous layer of the mammalian lower 
intestine (15, 16) A summary of all E. coli enteric pathotypes is provided in Figure 1. E. 
coli, as a species, are generally commensal bacteria that can cause opportunistic urinary 
tract infections, meningeal disease or enteric diseases depending on the virulence factors 
present (16). Several major E. coli pathotypes (such as STEC) have emerged in the 
evolutionary history of E. coli through the transfer of virulence factors from other 
bacterial species by way of mobile genetic elements such as pathogenicity islands, 
transposons, and plasmids (17). Knowledge of the existence of E. coli-associated Shiga 
toxin and its role in human health emerged in 1983, when a study by Karmali et al (18), 
discovered a substance acutely lethal to African green monkey kidney (Vero) cells in the 
filtered stools of children suffering HUS that was antigenically indistinct from the toxin 
produced by Shigella dysenteriae. This study was published in the same year as another 
investigation by Riley et al (19), examining the stools of patients involved in outbreaks 
of HC, where an unusual serotype of E. coli, expressing the somatic (O) antigen 157 and 
the flagellar (H) antigen 7, was implicated as the causative organism (20). Subsequent 
investigations have led to widely accepted associations between the presence of E. coli 
expressing the Shiga-like toxin and cases of HUS and HC (20), and also revealed a 
secondary variant of the toxin that could not be inactivated by anti-Shigella toxin 
antibody. These two variant types of the toxin have come to be referred to as Stx1 
(antigenically similar) and Stx2 (antigenically distinct) (20). Although more recent 
studies have linked diarrhoeal diseases directly to the genes of virulence factors carried 
by both O157 and non-O157 STEC strains (21, 22), much of the diagnostic efforts of the 




Figure 1: Pathologies of gastrointestinal pathotypes of E. coli, including enterotoxigenic E. coli 
(ETEC; depicted here with heat-labile (LT) and heat stable (ST) enterotoxins), enteroaggregative 
E. coli (EAEC), diffusely-adherent E. coli (DAEC), and enteroinvasive E. coli (EIEC). E. coli 
expressing Shiga toxins (STEC) are often associated with the characteristic EPEC attachment 
factors intimin and bundle forming pili (BFP), which permit close association to, and microvillus 
effacement of, intestinal enterocytes. Shiga toxin and the EPEC attachment factors work together 
synergistically to give an enhanced likelihood of progression to severe haemorrhagic diseases, 
and this co-interaction forms the basis of the classification enterhaemorrhagic E. coli (EHEC). 




1.3 Pathology of STEC and the role of intimin (eaeA)  
The Shiga toxin variants Stx1 and Stx2 are defined as AB5 multiunit toxins, and are 
encoded on two mobile genetic elements (H19B and 933W, respectively) referred to as 
temperate lambda bacteriophages (23). These prophages are composed of double-
stranded DNA, typically flanked by functioning insertion sequences, and have the ability 
to insert themselves into the chromosomal DNA of E. coli through the action of 
recombinases (24). The prophages display considerable genetic mosaicism (25). These 
elements permit the host E. coli to express Shiga toxin and, if functionally intact, can also 
multiply and excise themselves from E. coli genomes through integrases and phage-
mediated lysis under conditions that promote lysogenic behaviours (26-28). The toxins 
expressed by the Stx genes form a protein complex composed of two subunits; a single 
30 kDa A subunit attached to five identical 7 kDa non-covalently pentamerically-bound 
B subunits (15). The B subunit pentamer component of the toxin binds to 
glycosphingolipid globotriosylceramide (Gb3) receptors of absorptive villi and Paneth 
cells in the mammalian intestine, and globotetraosylceramide (Gb4) surface receptors in 
renal glomerular cells and brain endothelia (15, 17, 26, 29). The binding by B subunits 
promotes the internalisation of the toxin complex, whereupon the A subunit induces 
apoptosis of the target cell through the depurination of 28S eukaryotic ribosomal RNA, 
effectively halting all protein synthesis in the endoplasmic reticulum (15, 29). The toxins 
are able to cause bloody and non-bloody diarrhoea through the killing of intestinal 
endothelial cells, although there is some speculation as to whether this is through direct 
killing or indirectly by the toxin inducing mesenteric ischaemia in the regional 
vasculature (6). The toxins are also able to translocate across the gastrointestinal 
endothelia by an unresolved transcellular pathway and enter the systemic circulation, 
from where it is documented to have a host of pathological thrombotic and 
immunomodulatory effects on both the renal glomerulus and systemic microvasculature 
(15, 30) A histological section showing Shiga toxin-mediated formation of a renal 
thrombus is shown in Figure 2. The mechanism by which the toxins traverse the 
circulation remains a point of conjecture amongst researchers (31), and the systemic 
effects are not usually accompanied by bacteraemia (30). It should be noted at this point 
that Stx1 and Stx2 have variable toxicity; Stx2 toxins are noted to have at least a 100-
fold higher toxicity against renal endothelial cells than Stx1 (5, 15) due to differences in 
the DNA sequences encoding the toxin components (32). As a result, Stx2 is the variant 
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Figure 2. Thrombus (arrow) in an arteriole of renal glomerular tissue as induced 
by Shiga toxin-mediated killing of Gb3-receptor expressing renal tissue. This 
histology section is from a fatal case of postdiarrhoeal HUS. 
Figure sourced from Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing 




most often associated with clinical cases of STEC and the progression of such cases to 
the more severe systemic complications of the disease such as HC and HUS (15, 32, 33). 
Stx2 is also noted to have a number of subvariants (Stx2, stx2c2, stx2d, stx2e, and stx2f) 
each with varying toxicity (34, 35). Perhaps unsurprisingly, O157 serotypes associated 
with clinical symptoms are generally found to have very high carriage rates of the Stx2 
toxin variant, usually in preference to Stx1, although comparable carriage rates may be 
seen outside this serogroup (21, 32, 36). The enhanced virulence of serotype O157:H7 
may be attributed to accessory virulence factors carried on a highly conserved 92-104 kb 
nonconjugative F-like plasmid referred to as pO157 (15, 37). pO157 contains over 100 
open reading frames encoding putative virulence factors such as proteases, haemolysins 
and adhesins on a heterogeneous mix of prophages, transposons and genetic elements 
thought to have evolved to aid intestinal colonisation in cattle (15, 16, 38). The virulence 
factors encoded on pO157 are obliquely related to O157:H7 infection; HUS-causing 
strains do not consistently have the full complement of putative virulence factors (39), 
and the pathogenicity of the plasmid in concert with Shiga toxin is somewhat muddled 
due to conflicting findings and heterogeneity in the expression of factors among strains 
(15, 40).  
Another notable virulence factor, and one with particular relevance to the pathogenesis 
of STEC and enteropathogenic E. coli (EPEC), is the adherence factor intimin, also 
referred to by its DNA encoding sequence eaeA. Intimin is a 94 kDa bacterial outer 
membrane protein encoded within a 35-42 kb mobile pathogenicity island referred to as 
the Locus of Enterocyte Effacement (LEE) (5). The LEE itself contains 41 open reading 
frames, highly conserved in EPEC, that encode a syringe-like type III secretion system, 
capable of injecting over 50 bacterial effector proteins directly into the cytosol of 
eukaryotic cells (15, 16). Intimin itself serves as an anchoring ligand on the bacterial cell 
surface for receptor proteins injected by the secretion system, thereby permitting close 
association to affected enterocytes (41, 42). These effector proteins, in conjunction with 
intimin, then permit LEE-positive E. coli to reshape the actin cytoskeleton of intestinal 
epithelial cells and form characteristic 10 µm pedestal formations on the cell surface, as 
shown in Figure 3 (41, 43). The LEE mechanism is also responsible for the formation of 
attaching and effacing (A/E) lesions, a characteristic debriding of microvilli on intestinal 
epithelial cells (5) (see Figure 3). Both the A/E lesions and pedestal formation are the 
defining histological characteristics of EPEC, and are thought to effect diarrhoea through 
7 
 
Figure 3. Pedestal formation and A/E lesions of EPEC and EHEC. The actin cytoskeleton 
remodelling ability of the E. coli LEE mechanism manifests as characteristic pedestal 
formations on the surface of intestinal epithelial cells underlying LEE-carrying E. coli. (a) 
depicts the pedestals as visible by scanning and transmission electron microscopy. (b) depicts 
normal intestinal microvilli, while (c) shows their characteristic effacement by the LEE 
mechanism. 
Picture (a) sourced from Campellone KG. Cytoskeleton-modulating effectors of 
enteropathogenic and enterohaemorrhagic Escherichia coli: Tir, EspFU and actin pedestal 
assembly. The FEBS journal. 2010;277(11):2390-402. 
Pictures (b) and (c) sourced from Mainil JG, Daube G. Verotoxigenic Escherichia coli from 






aiding diffuse adherence and motility of LEE-positive bacteria across epithelial surfaces 
(41, 42, 44). Intimin is not the only adherence factor in EPEC (45), but mutant analysis 
indicates it is crucial for the optimal function of the LEE mechanism (42, 44), and is 
regarded as the principal adhesin for the formation of close associations with intestinal 
epithelial cells and colonisation of the intestine by EPEC (15, 42). Due to the integral 
role of intimin in the formation of A/E lesions, the presence of the encoding gene, eaeA, 
acts as a satisfactory marker of the LEE mechanism of EPEC bacteria (45, 46). Although 
diarrhoea can certainly arise in LEE-negative STEC infection (41), and although the 
exact pathogenicity also relies on accessory virulence determinants (as shown in Table 
1) and host factors (32, 39, 47), the close association formed by the components of the 
LEE mechanism are recognised to greatly aid in the delivery of Shiga toxins to 
enterocytes and the underlying mesenteric vasculature in vivo (41). Most of the strains 
isolated from outbreaks of HC and HUS and those infections with more severe symptoms 
typically express both Shiga toxin and intimin (21, 33, 36), and are usually designated 
along with carriage of pO157 as the pathotype enterohaemorrhagic E. coli (EHEC) (39). 
The tendency for HUS patients to form strong antibody responses to intimin and other 
LEE components underscores the importance of the adhesion determinant in advanced 
STEC infections (16). 
1.4 Disease course and therapy 
Due to the confluence of host and virulence factors, as well as the infecting STEC or 
EHEC strain and accessory virulence factors present, the clinical spectrum of STEC is 
appreciably broad and patient outcomes may be difficult to predict. Symptoms can range 
from asymptomatic or subclinical (and hence unreported) diarrhoea to severe 
haemorrhagic and neurological complications and death. Clinical cases of STEC 
infection typically present as self-limiting, with painful abdominal cramps and non-
bloody diarrhoea that occur 1-8 days post ingestion (4, 43), but may progress to bloody 
diarrhoea without concomitant fever or raised leucocyte count after a further 2-7 days 
(15, 43). The progression to HC and HUS is difficult to predict (27), but is especially 
frequent in children <10 years of age (43, 48), the immunocompromised and the elderly, 
with the highest rates associated with EHEC (stx+, eaeA+) and particularly O157 
serotypes (15, 43). The rate of progression to HC and HUS is generally 10-15%, subject 
to patient factors, the accessory virulence factors present, and the Shiga toxin variant 
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TABLE 1: Accessory virulence factors associated with enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) E. coli pathotypes 
 





LEE PAI selC, pheU, pheV, 
yehV, yecE, ssrA, 
wrbA, z2577† 
T3SS (cytoskeletal reorganisation), Tir (translocated intimin receptor), 
Map (mitochrondrial membrane potential disruption), EspB, EspF, EspG, 
EspH and EspZ (T3SS effector proteins) 
EAF (pMAR2) Plasmid Not applicable BFP (adhesin) 
PP2 Phage ybhC_ybhB EspJ, Cif (blocks mitosis) and NleH 
PP4 Phage torS_torT NleD, NleC, NleB and NleG 
PP6 Phage ompW NleF, NleH and NleA 
IE2 PAI serX NleE and LifA-like 





LEE PAI selC T3SS (cytoskeletal reorganisation), Tir (translocated intimin receptor), 
Map (mitochrondrial membrane potential disruption), EspB, EspF, EspG, 
EspH and EspZ (T3SS effector proteins) 
pO157 Plasmid Not applicable EspP, toxinB, LifA/Efa (lymphocyte adhesion/activation inhibition), 
StcE (T3SS complement disrupter), HlyA (cell lysis) and EhxA (cell 
lysis) 
Sp3/CP-933K Phage ybhC_ybhB NleB, NleC, NleD and Cif (blocks mitosis) 
Sp9/CP-933P Phage yciE NleA (also known as EspI), NleF, NleG, EspM, NleH and EspO 
Sp14/CP-933U Phage serU TccP and EspJ 
Table adapted from Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nature Reviews Microbiology. 2010;8(1):26-38 
with function information from Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nature Reviews Microbiology. 2004;2(2):123-40.  
PAI: pathogenicity island. LEE: Locus of Enterocyte Effacement. IE: insertion element. PP: prophage. EAF: EPEC adherence factor 
† Insertion sites as mentioned by Hauser E, Mellmann A, Semmler T, Stoeber H, Wieler LH, Karch H, et al. Phylogenetic and molecular analysis of 
foodborne Shiga toxin-producing Escherichia coli. Applied and environmental microbiology. 2013;79(8):2731-40. 
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expressed (2, 26, 48). HUS itself is characterised by the onset of microangiopathic 
anaemia (damaged erthryocytes), thrombocytopenia (reduced platelet levels) and may be 
accompanied in adults by thrombotic thrombocytopenic purpura (TTP; a diffuse 
formation of microangiopathic thrombi, often with concurrent neurological 
abnormalities) (20, 49). HUS is the clinical manifestation of Shiga toxin-induced damage 
of the kidney glomerular vasculature, and may even result in long term sequelae such as 
renal insufficiency and neurological aberrations (43). Overall, 3-5% of HUS cases are 
fatal (15). Generally, non-O157 infections have a milder course than that of O157:H7; 
diarrhoea has a greater likelihood of being bloody (>90% chance with O157 vs 60%), 
abdominal cramping is usually more severe, and the need for hospitalisation (43% vs 
18%) and progression to HUS (10-15% vs <10%) is more pronounced in O157 infection 
(7). These tendencies can largely be related to the carriage of eae and stx2 virulence 
factors; stx2 is associated with HUS in both O157 and non-O157 STEC infection. On the 
other hand, carriage of stx2 is generally less common in non-O157 STEC, usually in 
favour of the less toxic stx1 (21, 32, 36). O157:H7 and disease causing non-O157 STEC 
generally have very high carriage rates of eae (36), and combined eae and stx2 carriage 
is regarded as a stronger predictor for bloody diarrhoea and HUS than the presence of 
serogroup O157 in multivariate analysis (50).  The HC that accompanies severe STEC 
or EPEC infection can mimic other intestinal diseases such as Crohn’s disease and induce 
elevated faecal calprotectin levels, while chronic STEC infections may result in irritable 
bowel syndrome (IBS) (15). Many physicians have an incomplete understanding of 
STEC infection and do not consider non-O157:H7 infection as part of a differential 
diagnosis (51). The clinical presentation of STEC infection may also potentially lead to 
confusion with other gastrointestinal disorders such as intussusception, appendicitis, 
inflammatory bowel disease (IBD), or infection with Clostridium, Shigella, Yersinia, 
Salmonella, or Campylobacter species (20, 27, 52, 53). 
EPEC infection typically presents as a self-limiting, acute, watery diarrhoea with 
vomiting and low grade fever, although some instances of protracted EPEC diarrhoea 
have been described (43). EPEC infection is a significant contributor to infant diarrhoea 
in developing countries (43), and although comparable prevalences have not been seen 
in infants of developed nations since the 1960s, genetic profiling indicates EPEC may 
still be significant to children’s diarrhoea (43, 54). 
11 
 
Treatments options for STEC infections are largely supportive, as antibiotics that induce 
DNA damage in E. coli have a tendency to activate a lysogenic SOS response in the 
Shiga prophage and cause upregulation of the expression of the Shiga toxin (35). As a 
result, treatments involving quinolones, ciprofloxacin, in addition to antimotility agents, 
are contraindicated in STEC infection, having been associated with increased incidences 
of progression to HUS (15, 30, 55). Parenteral volume expansion with liberal amounts of 
intravenous fluids (15, 56), particularly in conjunction with peritoneal dialysis is the 
recommended course for advanced cases of STEC infection (27, 31). Early 
administration of the monoclonal anti-Shiga toxin antibody eculizumab is also 
recognised to increase platelet counts and limit toxin-mediated neurological effects (31, 
56). The development of vaccines capable of stimulating a strong antibody response 
against pathogenic E. coli antigens such as intimin (35, 57), is currently ongoing, albeit 
hampered by the difficulty in finding an appropriate animal model (43).  
1.5 Epidemiology 
The global impact of STEC infection is difficult to estimate because of inconsistencies 
in reporting methods between countries and the varying prevalences of detected and 
undetected serotypes within such countries. The most recent estimate, a meta-analysis of 
papers and databases of 21 countries, places the global number of acute STEC infections 
at approximately 2.8 million per year, with an estimated 3890 cases of HUS, 270 cases 
of end-stage renal disease, and 230 mortalities (58). STEC infections are usually sporadic 
and generally affect children and the elderly, with the typical source of infection being 
the ingestion of contaminated foodstuffs (43). The natural reservoir of STEC is the 
intestine and rectum of cattle, and the contamination of processed beef carcasses 
combined with modern mass distribution is recognised as the classic cause of larger 
outbreaks (5, 59, 60). STEC may also be carried by a variety of farmyard animals 
including sheep, goats, chickens, pigs and deer, with outbreaks traced to contact with 
these animals or consumption of improperly prepared foodstuffs (48, 61, 62). Infection 
with stx-  EPEC is mostly confined to diarrhoeal sporadic cases in children <2 years of 
age and outbreaks are usually related to contaminated weaning foods, milk formula and 
fomite transmission in nurseries and paediatric units (43). The shedding of EPEC in 
faeces may be asymptomatic in adult carers and older children, and so these are thought 
to be the natural reservoir of infant EPEC infection (43). An adult form of EPEC 
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diarrhoea may be observed in instances of an ingestion of a large inoculum and/or 
perturbed gastric acids (43). EPEC infection is associated with traveller’s diarrhoea in 
developing countries (43).   
In recent years, STEC outbreaks have also been associated with person-to-person spread, 
as well as contaminated or unpasteurised milk, juice, sprouts and other vegetables (2). 
The durability of STEC in bovine faecal matter and groundwater is thought to permit the 
spread of STEC to mass-produced crops via effluent run-off and exposures through 
environmental water sources (35, 57, 63, 64). Perhaps the most notable case of an 
outbreak of STEC infection in recent times was the 2011 O104:H4 outbreak in Germany, 
involving an especially virulent strain of non-O157 E. coli that caused over 4000 STEC 
illnesses, 908 cases of HUS and 90 deaths (55). The source of infection was ultimately 
traced to a batch of contaminated fenugreek sprouts (55), and although the strain did not 
employ intimin as its primary attachment factor (65), the outbreak served to highlight the 
contribution of non-O157 STEC to human disease in developed countries. Non-O157 
STEC infection is usually dominated by the serogroups O26, O111, O145, O103, O45 
and O121, which together typically comprise ~70% of the non-O157 STEC infections in 
many countries and are well represented amongst isolates retrieved from sufferers of 
HUS, TTP and bloody diarrhoea (32, 36). These ‘big six’ or ‘gang of five’ (some 
researchers omit O45) possess many of the virulence factors and associations to 
complicated enteric disease seen in O157:H7 strains (9), although the dominant strain 
may vary from country to country (see Table 2). The contribution of the ‘big six’ to STEC 
disease is noted to be underreported (7), and international data suggests that the 
proportion of STEC disease caused by non-O157 serogroups is increasing (7, 8, 66, 67).  
In New Zealand, the annual notification rate for all STEC infection as recorded by ESR 
has been increasing since 1997, peaking with 4.6 cases per 100,000 in 2013 (203 cases; 
see Figure 4) (13). The Enteric Reference Laboratory at ESR identified 88.1% of received 
STEC isolates as being of the serotype O157:H7 in 2014, with the remainder confirmed 
as non-O157 E. coli (10.2%) or of undetermined serotype, a result analogous to that of 
the previous year (68). Most STEC cases are unrelated or occur in small outbreaks 
confined to a family or geographic region with exposure to contaminated farmland or 
private water supplies as primary risk factors (69). Studies involving serogrouping of 
New Zealand STEC in cases of human illness indicate New Zealand has usual and 
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TABLE 2: Prevalent and predominant STEC serogroups by country 
 
Country/Continent Prevalent serogroups 
Predominant serogroup (O157 vs non-
O157) 
United States O157, O26, O111, O103, O121, O45, O145 O157 
Canada O157, O55, O125, O26, O126, O128, O18 O157 
South America O1, O2, O15, O25, O26, O49, O92, O11 Non-O157 
United Kingdom O157 O157 
Continental Europe O157, O26, O111, O104, O103, O128, O91, 
O113, O2, O9, O145 
Both 
Australia O157, O111, O26 Both 
Japan O157, O26, O111 O157 
Table adapted from Vanaja SK, Jandhyala DM, Mallick EM, Leong JM, Balasubramanian S. Enterohemorrhagic and other Shiga toxin-
producing Escherichia coli. In: Donnenberg M, editor. Escherichia coli: Pathotypes and principles of pathogenesis. 2 ed: Academic Press; 
2013. p. 121-82. 
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Figure 4. Number of all STEC infections reported to ESR by community and hospital based diagnostic laboratories 1997-2014. The number 
of notifications of STEC infections has been increasing since 1997, with typically 90% of cases recognised to be caused by E. coli O157:H7. 
Graph sourced from Notifiable diseases in New Zealand: Annual Surveillance Report. The Institute of Environmental Science and Research, 
2014. Available at: https://surv.esr.cri.nz/surveillance/annual_surveillance.php   
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unusual non-O157 serogroups (O26, O84, O103, O123, O176, and O180), likely related 
to agricultural practice (70-72). Due to deficiencies in current diagnostic approaches in 
STEC detection, it is entirely plausible that these or other serotypes may have an 
unappreciated role in diarrhoeal disease in New Zealand. 
1.5 Diagnostic techniques 
E. coli O157:H7 is currently a notifiable disease in New Zealand, and in accordance with 
recommendations by the CDC (2), E. coli isolates presumptively identified as O157:H7 
are sent by hospital and community diagnostic laboratories to the Institute of 
Environmental Sciences and Research (ESR; a Crown Research Institute) for 
confirmation as STEC, serotyping and inclusion in monthly and annual Public Health 
Surveillance reports (such as those available at 
https://surv.esr.cri.nz/surveillance/surveillance.php). Like many diagnostic laboratories 
in the United States and Europe (53, 67, 73), the isolation of O157:H7 by New Zealand 
laboratories is typically based on the selective and differential culture of faecal samples 
on Sorbitol-MacConkey Agar, supplemented with cefixime and potassium tellurite (CT-
SMAC; as available from Fort Richard Laboratories in New Zealand). The vast majority 
of E. coli O157:H7 strains, unlike most commensal E. coli and ~95% of enteric bacteria 
(43, 74), are unable to ferment the carbohydrate sorbitol within 24 hours, and the lack of 
fermentation by such colonies will typically render them colourless in the presence of 
agar pH indicators (6) (see Figure 5). SMAC-based plating of faeces is appropriate for 
the differentiation of O157:H7, but has a number of limitations. The first and perhaps 
most important shortcoming is that the majority of non-O157 E. coli serotypes are 
sorbitol-fermenting (8), and so potentially these Shiga-toxigenic E. coli would not be 
discriminated from other enteric bacteria with use of this medium, nor sufficiently 
reported in national surveillance datasets. When considered alongside international and 
domestic trends citing increases in prevalence of non-O157 and all STEC infection, and 
considering the role of non-O157 within the New Zealand environment, the need for a 
prevalence study to determine the contribution of non-O157 to diarrhoeal disease is 
evident. This shortcoming should be considered in conjunction with the fact that the 
pathogenicity of certain strains of non-O157 is comparable to that of O157:H7. 
Furthermore, sorbitol-fermenting variants of O157 do exist, most notably strains of 
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Figure 5. SMAC agar. Among enteric bacteria, E. coli O157:H7 are near-uniquely unable 
to ferment the carbohydrate sorbitol within 24 hours, and so the use of SMAC-based media 
has become a popular screening method for O157:H7. Sorbitol non-fermenting colonies 
typically appear colourless (arrow) with the incorporation of Neutral Red as a pH indicator. 
17 
 
O157:H- (also referred to as O157:NM, or non-motile); a serotype of considerable 
pathogenicity encountered in Germany that is also tellurite sensitive (74, 75).  
The diagnostic algorithm in use at Southern Community Laboratories (SCL) at Dunedin 
Hospital is to perform confirmatory identification of sorbitol non-fermenting colonies 
with use of matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) and 
latex agglutination with O157 antibody analysis before sending live specimens of any 
O157 or sorbitol non-fermenting E. coli to ESR (76). The diagnostic algorithm is 
represented diagrammatically in Figure 6. This algorithm effectively precludes confusion 
with other enteric bacteria that may not ferment sorbitol (ie. Aeromonas) (73), or have 
antigens that cross-react with O157-specific antibodies (ie. Citrobacter freundii, 
Escherichia hermannii), but misses sorbitol-fermenting E. coli of any serotype (48). The 
rapid clearance of detectable STEC bacteria from the gastrointestinal tract (7-12 days 
after onset of diarrhoea, even in cases of HUS (77, 78)), the action of antibiotic regimens 
in-situ in faeces potentially inhibiting plate-based growth (78) and the fact that samples 
are usually taken several days after the onset of diarrhoea can conspire to limit detection 
of O157:H7 strains (27, 49, 77). Moreover, freeze-, pH-, or salt-stressed E. coli (as may 
be encountered in faecal samples that are kept on ice for live transport) are recognised to 
have compromised resistance to normally harmless selective agents such as cefixime and 
tellurite on plate media (79-81).  
An attractive alternative to the use of plate-based culturing are PCR-based assays, and 
many studies in recent years involving primer sequences capable of the amplification of 
virulence genes specific to E. coli have been successfully developed (46, 82, 83). PCR 
assays of processed faecal samples promise potentially the most sensitive, specific and 
economical method for the large-scale detection of pathogenic E. coli (83-85), and one 
configurable for the simultaneous detection of multiple E. coli virulence determinants 
(14, 86, 87). As PCR-based techniques are based on the multiplication of select specific 
genetic sequences within a sample, the technique is an alternative to culture-based 
techniques that hinge on the growth of isolates amongst other enteric bacteria. The use 
of quantitative real-time PCR (qRT-PCR) assay platforms, such as the Life Technologies 
ViiA™ 7 Real-Time PCR System, can potentially provide quantitative information on 
pathogenic E. coli without need for post-PCR processing (88). Pre-enrichment of faecal 
samples is recommended for PCR protocols established for the diagnosis of STEC 
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FIGURE 6: SCL STEC testing algorithm 
All diarrhoeic stools are 




 Cannot isolate Sorbitol 
non-fermenting E. coli 
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(monoclonal O157 antibodies) 
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Figure 6. STEC testing algorithm for diarrhoeal stools received by Southern Community 
Laboratories, Dunedin Hospital. This culture-based algorithm detects the E. coli serotype 
O157:H7 through sorbitol non-fermentation, MALDI-TOF identification and latex agglutination 
with monoclonal anti-O157 antibodies. Sorbitol non-fermenting E. coli isolates suspected of 





infections (56). The more rapid turn-around time for qRT-PCR can also allow for more 
rapid diagnoses of STEC infections, informing timely and accurate treatment (56), 
avoiding contraindicated antibiotics or invasive procedures, and permitting the early 
adoption of control measures in outbreak situations (2, 43). qRT-PCR reactions may also 
be configured so that multiple assays occur within the same reaction mix simultaneously, 
in a process referred to as multiplexing. Another avenue for PCR investigation is the 
relatively novel loop-mediated isothermal amplification (LAMP) technique (89). LAMP 
employs an alternative amplification mechanism to amplify target sequences, and has 
proven to be of use in diagnostic settings (90, 91). While LAMP is not amenable to 
multiplexing, the technique could be explored as a form of rapid, inexpensive screening 
of O157 STEC. There are currently no diagnostic measures in place for the screening of 
EPEC at Dunedin Hospital. 
1.6 Aims and Study Objectives 
The primary aim of the project was to develop and test a multiplex qPCR assay suitable 
for the detection of STEC and/or intimin carrying E. coli and to use this assay to 
determine the prevalence of these bacteria in diarrhoeic stools sourced from SCL, 
Dunedin Hospital. A secondary aim of the project was to develop the assay to be 
appropriate for use in a diagnostic setting, through maximising sensitivity of the test, 
adapting the assay for high-throughput testing, and simplifying pre-PCR extraction 
methods. A tertiary objective was to examine the prevalence of STEC or intimin-carrying 
E. coli in faecal samples set aside for prospective H. pylori or inflammatory bowel 





1. To develop a qPCR assay or assays capable of detecting STEC and EPEC 
in faecal samples 
 Validate a (preferably) multiplex PCR assay suitable for the simultaneous 
detection of STEC and intimin-carrying E. coli 
 Determine if the assay can be used to provide relevant quantitative 
information on STEC and/or intimin-carrying E. coli from patient samples 
 Use the assay to determine the prevalence of STEC and intimin-carrying E. 
coli in diarrhoeal stools sourced from Dunedin Hospital 
 
 
2. Adapt the diagnostic method to be suitable for use in routine medical 
laboratory testing 
 Evaluate the efficacy of a selection of DNA extraction techniques, and 
decide upon which would be most appropriate for large-scale screening of 
faecal diarrhoeal stools 
 Evaluate the effect of pre-enrichment on the sensitivity of the PCR assay to 
detect STEC or intimin-carrying E. coli within faecal samples with use of 
the selected DNA extraction method 
 Adapt assay conditions and the use of reagents to be as economical as is 
feasible 




3. Use the assay to survey prevalences of STEC and EPEC in diarrhoeal stool 
samples set aside for H. pylori or IBD testing in Dunedin Hospital  
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2 Diarrhoeagenic STEC and EPEC growth 
characteristics 
2.1 Introduction 
The detection of STEC through multiplex PCR assays has been well established in the 
scientific literature, with many studies in the past two decades detailing the efficacy of 
PCR to deduce the presence of E. coli-specific virulence determinants in a variety of 
mammalian faecal samples including human (14, 46, 86, 87, 92-95). The data derived 
from these and other studies has contributed greatly to the understanding of the 
epidemiology of STEC, but many diagnostic laboratories, even in developed countries, 
have yet to implement PCR-based technologies (2, 10, 96). For many laboratories, the 
cost of PCR reagents and specialist training is the main factor in deciding diagnostic 
algorithms, but the varying sensitivities of PCR based technologies must also be taken 
into consideration. The limit of detection of sorbitol-fermenting STEC on CT-SMAC 
based culture of naturally infected human faeces has been assessed to be 1 x 104 – 1 x 
106 CFU/g (97, 98). There is some variability in the limits of detection of STEC and other 
bacteria in faecal samples by various qRT-PCR methods (the limit of detection ranges 
from 3 x 102 to 1 x 105 CFU/g faeces) (87, 95, 99-101), and the sensitivity can be 
influenced by the amount of endogenous E. coli in faeces (95, 102). The low numbers of 
STEC during infection and the rapid clearance of the organism from the intestine 
necessitates highly sensitive testing for accurate reporting (73, 98, 103). Pre-enrichment 
of faecal samples in non-selective broth is recommended as a practical approach to boost 
the sensitivity of PCR assays (56, 73). Pre-enrichment is thought to have the dual benefits 
of increasing resident STEC populations beyond the limits of PCR-based detection whilst 
diluting the effect of faecal compounds that would normally be inhibitory to Taq 
polymerase (56, 104). Although the growth dynamics of E. coli in liquid media is 
arguably one the most well established concepts in microbiological research, studies on 
the dynamics of STEC culture growth in short incubation (<6 hours) is sparse. 
The following experiments were undertaken with the intent to evaluate the most 
appropriate liquid broth medium for the growth of a representative range of STEC strains 
in a timespan appropriate for use in a day-to-day diagnostic setting.  
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2.2 Materials and Methods 
2.2.1 Culture media 
The growth media for cultivation of the bacterial strains used in this study were sourced 
in dehydrated form, prepared according to the manufacturer’s instructions and autoclaved 
at 121°C for 15 minutes. The broths used were Lennox LB (Invitrogen) and agar 
(BactoTM, BD Diagnostics), EC broth (Fort Richard Laboratories), Trypticase Soy Broth 
(TSB) and agar (TSA) (BD Diagnostics), and Brain Heart Infusion (BHI) reductant (BD 
Diagnostics). 
2.2.2 Bacterial strains 
2.2.2.1  Standard Operating Procedure for STEC containment 
In accordance with the Department of Microbiology and Immunology Health and Safety 
policies and PC2 provisions, a Standard Operating Procedure (SOP) for the appropriate 
handling and disposal of STEC-containing culture material was devised (see Appendix 
1). 
2.2.2.2  E. coli O91:H-, O130:H11 and O84:HNM 
E. coli reference strains O91:H- (stx1+), O130:H11 (stx2+) and O84:HNM (eae+, stx1+) 
used in the study were obtained from the Enteric Reference Laboratory, The Institute of 
Environmental Sciences and Research (ESR; Wellington) (see Table 3). Initially, strains 
carrying only one of the stx variants under investigation were chosen on the basis of 
safety, although subsequent testing revealed O84:HNM to be also stx2+.  
2.2.2.3  E. coli O111:K88:H- and O157:H- 
E. coli reference serotype O111:K88:H- (eae+) was obtained from Dr. H Brooks’ culture 
collection (Dept. Microbiology and Immunology, University of Otago), and a stx- 
O157:H- strain was obtained from Dr. Michelle McConnell’s culture collection (Dept. 
Microbiology and Immunology, University of Otago). See Table 3 for strain reference 
information. 
2.2.3 Storage and Culture 
E. coli O91:H-, O130:H11, and O84:HNM were resuscitated from lyophilised ESR stock 
cultures by resuspension in TSB and application to TSA for overnight incubation at 37°C 
under aerobic conditions. E. coli O111:K88:H- and O157:H- were received in skim milk 
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TABLE 3: BACTERIAL STRAIN INFORMATION 
Serotype NZRM ESR ERL No.† Ref No. eae stx1 stx2 Isolate source 
O91:H- 4152 ERL97-3929 CDC 97/30206 Negative Positive Negative Ovine (Meat) 
O130:H11 4162 ERL02-1805 - Negative Negative Positive Human 
O84:HNM 4163 ERL03-1204 - Positive Positive Negative Human 
O111:K88:H- 735 - NCTC 911 Positive Negative Negative Infant NEC* 
O157:H7 3647 - - (found to be positive) Negative Negative Infant NEC* 
*NEC = Necrotising Enterocolitis           †Enteric Reference Laboratory, Environmental Sciences and Research 
24 
 
stored at -80°C, resuspended in TSB, incubated overnight at 37°C and plated on TSA. 
After Gram staining, the strains were stored in Microbank (ProLab Diagnostics) bead 
stocks at -20°C. Bacteria used for the Optical Density (OD) curve, broth comparison and 
qPCR extraction experiments were plated on TSB from these bead stocks and incubated 
at 37°C overnight under aerobic conditions. Due to the propensity of STEC to lose stx-
bearing prophages through multiple culture passages, passaging of more than five 
derivatives of a bead stock was avoided. 
2.2.4 Gram staining of bacterial strains 
All of the E. coli strains were Gram stained and examined under high magnification 
(x100 oil lens) before culture and qRT-PCR work to confirm the identity of the bacterial 
growth and check for possible contaminants. Culture plates were examined to ensure 
consistent colony morphology. 
2.2.5 Standard OD curve 
OD standard curves of strains O91:H-, O130:H11, O111:K88:H- and O84:HNM were 
prepared to provide a fast and reliable means to determine Colony Forming Units (CFU) 
mL-1 from optical density measurements. 
2.2.5.1  Turbimetric measurement (Optical density) 
Growth from single colonies of each of the E. coli strains given above were suspended 
separately in 10 mL of TSB broth and cultured under atmospheric conditions at 37°C for 
18 hours. The broth cultures were diluted 2-fold in sterile TSB diluent and 0.1 mL of 
each dilution was dispensed into a 96-well flat bottom tissue culture plate (Falcon®) in 
triplicate. Using sterile TSB as the blank, the optical density of the dilutions was read by 
spectrophotometric absorbance at 600nm with a Varioskan plate reader (Thermo 
Scientific Research Edition, using SkanIt software v2.4.5.9). Any values that were 
negative after normalising against the blank density were disregarded in subsequent 
calculations. 
2.2.5.2  Viable Bacterial Count 
The overnight broths were diluted 10-fold in sterile PBS and 0.1 mL of the 10-5, 10-6, and 
10-7 dilutions were dispensed in triplicate to TSA plates and incubated overnight under 
aerobic conditions at 37°C. After overnight incubation, the bacterial colonies on the plates 
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with a colony count between 20-250 colonies were counted, and the average of the 
triplicate cultures was recorded. An uninoculated culture was included with all cultures 
and subsequently plated to check for broth contamination. 
2.2.5.3  Standard Curve 
A standard curve was created for each of the bacterial strains by plotting the absorbance 
obtained from each dilution against the CFU mL-1 obtained from the bacterial count using 
the Microsoft 2013 Excel software program. 
2.2.6 Enrichment Broth Comparison 
2.2.6.1  Turbimetric Measurement (Optical density) 
To determine the optimal enrichment broth for short-phase E. coli culture conditions, an 
overnight culture of each of the E. coli strains (O111:K88:H-, O91:H-, O130:H11 and 
O84:HNM) was diluted to 2x103 CFU mL-1 in each of the documented sterile broths 
(BHI, EC, LB and TSB) based on optical density measurements as described above. This 
inoculant (1 mL) was dispensed to two sets of 20 mL Universal bottles, each containing 
9 mL of each of the four broths. One set was incubated under aerobic conditions for 3 
hours after a thorough mixing by pipette aspiration. The culture (0.1 mL) was dispensed 
to 3 wells of a 96-well plate and the absorbance at 600nm was measured against an 
equivalent uninoculated blank incubated alongside the inoculated cultures. The other set 
was incubated for 6 hours and subjected to the same measurement. Each of the strains 
were subjected to this experiment twice, such that 2 x 3 hour OD600nm readings and 2 x 6 
hour OD600nm readings, each in triplicate, were obtained. One of the two cultures with 
O111:K88:H- was inoculated with 2 x 104 CFU of the bacterium  Using standard curves 
for each of the strains, the absolute CFU mL-1 of the incubated cultures was calculated 
and graphed using Microsoft Excel 2013 and ANOVA analysis (with Tukey’s Multiple 




2.3.1 Standard OD600nm curve for Escherichia coli strains used 
The OD600nm readings and CFU calculated from plate readings for each of the E. coli 
strains are expressed graphically in Figure 7. The resultant equations (eg. y = 2E x -10x 
+0.0071 for E. coli stain O111:K88:H-) were used as a basis of calculating CFU mL-1 
from broth culture ODs in subsequent experiments. 
2.3.2 Broth comparison experiment results 
The growth of the E. coli strains O111:K88:H-, O91:H-, O130:H11 and O84:HNM after 
six hours of incubation at 37°C under aerobic conditions is shown in Figure 8. The 
cultures that were incubated for 3 hours did not return OD600nm values when normalised 
against their respective blanks (sterile broth) and so were not included. The 6 hour values 
showed considerable variability in the growth of the different E. coli strains in the broths, 
and also in the comparative performance of the broths across the strains. EC broth was 
found to have the poorest growth overall, with OD600nm readings so low as to be 
indistinguishable from the uninoculated broth control after 6 hours of incubation for 
strains O91:H-, O130:H11 and O111:K88:H- (when the O111:K88:H- cultures were 
inoculated with the standard amount (2 x 103 CFU mL-1) of bacteria). The only instance 
of this broth appearing to perform better than any other occurred during testing with 
O84:HNM, however the differences in mean calculated CFU with that of BHI were not 
judged statistically significant (p <0.05) by ANOVA analysis. The broth that appeared 
to provide the best growth overall was BHI, however this appeared to be heavily strain 
dependent, with comparatively poor growth in this broth by O84:HNM (BHI growth was 
significantly lower than TSB (p <0.05) and considerably lower than LB (p <0.001)). 
Although TSB had significantly lower growth (p <0.001) than BHI for O111:K88:H- 
when using the higher inoculant (2 x104 CFU mL-1), this broth was not statistically lower 
than BHI for any of the other strains, and did not display the variability in comparative 
growth as seen with LB. One of the broth comparisons conducted for O111:K88:H- used 
a higher inoculum, and is expressed separately in Figure 8. 
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Figure 7. Standard CFU-OD curves. The standard curves shown here are based on the mean Optical Densities (600 nm) of 2-fold dilutions of each of the 
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Figure 8. Comparison of growth of the listed serotypes of Escherichia coli over 6 hours at 37OC, aerobic conditions. The broths shown are Brain Heart Infusion (BHI), E. coli broth (EC), Lennox 
Luria Broth (LB) and Tryptic Soy Broth (TSB). All broths were inoculated with 2 x 104 CFU (2 x 103 CFU mL-1 of broth) of the E. coli strains shown, except those depicted in the O111:K88:H- #2 
graph, which were inoculated with 2 x 105 CFU (2 x 104 CFU mL-1). The error bars depict the standard error of the mean (SEM) with the graphs of O111:K88:H- each composed of triplicate OD 
reads. The other graphs represent two separate tests, like that of O111:K88:H11, but with the data merged into one graph as the growth conditions were exactly the same. Any values that returned 
negative after normalisation against a sterile blank were excluded. The results show considerable variability in the performance of the broths across the E. coli strains tested. EC broth provides the 
least optimal conditions, with what growth that is able to be detected by OD600nm usually significantly less ( p = <0.05)  than the growth seen in the other broths. Although BHI and LB did permit 
effective growth of the E. coli strains shown, the growth appeared to be highly dependent on the strain and inoculation amount, TSB was judged to be the most consistent supporter of short phase 





The intent of the broth comparison experiment was to determine which commonly used 
non-selective broth would be most suitable for the pre-enrichment growth of STEC. TSB 
was found to be the best for growth of the STEC reference strains over a 6 hour 
incubation, with EC broth performing poorly compared to the other broths. The 
experiment assessed a shorter incubation time that could be incorporated within a daily 
diagnostic schedule. Previous research has indicated this minimises overgrowth of non-
pathogenic E. coli, preventing STEC detection through metabolic crowding of the media 
(105). One of the complications in STEC research, aside from the low numbers of 
pathogenic strains during active infection (103), is the effect of selective agents. The 
choice of non-selective media was based on the findings of Rocha et al (106) and 
Fukushima et al (105), who conducted testing of STEC strains in antibiotic-
supplemented media. The addition of antibiotics such as vancomycin, cefsulodin and 
novobiocin does improve the selectivity of enrichment broths for E. coli over that of other 
enteric bacteria for longer incubations (105), but are demonstrated to constrain the 
growth of E. coli in incubations of 6 hours or less (106). Instances of injury or stress, as 
may be encountered in faecal environments, are recognised to predispose pathogenic E. 
coli strains to the action of selective agents (73, 107, 108). There is also some evidence 
of novobiocin, cefsulodin and vancomycin causing selective inhibition of certain strains 
of STEC, such as strains of O91 and O111 serogroups (109). TSB and EC broths were 
selected for comparison on account of their ubiquity; a review conducted by Vimont et 
al (110) concluded TSB and EC were the most frequently used broth for the isolation of 
STEC, a fact corroborated by many instances of their use in other studies (56, 62, 64, 85, 
103, 105-109, 111-116). BHI and LB were readily accessible to the researcher and were 
included in comparisons on the basis of their amenability to short-phase incubation, with 
demonstrable examples of these broths fostering increases of STEC populations from 
environmental sources within 2 hours of incubation (93, 104, 109). EC was noted by 
Rocha et al to have impeded growth in comparison to the other assessed broths, but he 
placed emphasis on a ciprofloxacin additive as being a root cause (106). In considering 
the restrained growth of STEC within EC broth, it was concluded that the media was not 
wholly non-selective; a later review of EC constituents revealed bile salts (as an agent 
selective for enteric bacteria) and that this likely retarded the short-term growth of STEC 
in the absence of ciprofloxacin (81, 106). In considering the applicability of pre-
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enrichment procedures to a diagnostic setting, it was decided to base the use of TSB for 
3 hour incubations by interpolating the 6 hour results of the comparative broth 
experiment as the plate reader could not detect changes in broth OD at 3 hours. In 
retrospect, this decision should have been supported with comparative plate counts 
before and after 3 hours TSB incubation similar to that conducted later in the faecal 
spiking experiments. Incubations of 2-3 hours to ‘resuscitate’ enteric bacteria has 
precedents in the literature (73, 92, 108), and data from Fukushima et al and Rocha et al 
supported the use of 3 hour TSB culture to boost STEC CFU even in the presence of 
other Gram negative bacteria likely to be encountered in faecal matrices (105, 106). 
Immunomagnetic beads, despite their use in improving sensitivity (98), are not generally 
adopted by diagnostic facilities on account of cost and labour requirements (104). The 
use of buffered peptone water for the resuscitation of injured STEC and the use of 42°C 
incubations for better selectivity for E. coli among other enteric bacteria remain avenues 
for future pre-enrichment investigations (105, 107, 117).  
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3 Detection of STEC and EPEC in faecal 
samples with use of qPCR 
3.1 Introduction 
One of the frontiers in modern diagnostic research is the adoption of molecular-based 
techniques for use in the diagnosis of infectious disease, with many areas of research 
focussed on testing the validity of PCR-based assays for the detection of STEC (12, 86, 
87, 92, 95, 114, 118-121), and comparing these with existing culture-, immunological-, 
and biochemical-based techniques employed in clinical laboratories (56, 98, 99, 114, 
122). PCR is based on the extracellular amplification of customisable DNA sequences 
under thermocycling conditions, and the technique can be tailored to detect specific 
genetic markers independent of host cell viability. Currently, the diagnosis of STEC in 
diagnostic laboratories centres on the characteristic inability of one particularly virulent 
serotype, O157:H7, to ferment sorbitol, with no phenotypic markers available to 
discriminate other sorbitol-fermenting serogroups of STEC from non-pathogenic E. coli 
(43, 82). PCR-based assays, then, could be employed in diagnostic laboratories to 
circumvent the restrictions imposed by culture-based techniques and match diagnosis 
directly to the presence of E. coli virulence factors known to have causative roles in 
STEC disease (22, 36). qRT-PCR assays are the latest iteration of PCR technology, and 
offer the potential to detect DNA in the femtogram range (123). Like conventional PCR, 
qRT-PCR is based on the amplification of specific DNA fragments, but engineered to 
produce increased fluorescence in proportion to the amplified DNA sequence through 
the use of fluorescent hydrolysis probes or DNA-intercalating dyes such as SYBR green 
(for an explanation of qRT-PCR with use of SYBR green or hydrolysis probes like those 
used by TaqMan, see Figure 9) (88). The name ‘real-time’ refers to the continuous 
monitoring of fluorescence by qRT-PCR platforms during thermocycling; providing the 
amplification efficiency of the assay is suitable, the cycle threshold value (the point at 
which the fluorescence is deemed to be statistically significant) should be inversely 
proportionate to the amount of the target sequence (46, 88, 123). In this way, qRT-PCR 
can also provide quantitative information on a DNA sequence within a sample, and 
potentially provide information of clinical importance (88). Multiple primer and probe 
sets can be combined within a single reaction, and so there exists the potential to develop 
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Figure 9. Principles of RT-PCR methods using SYBR Green and hydrolysis probes. SYBR 
Green acts as an intercalating dye that greatly increases in fluorescence upon intercalating 
with double stranded DNA, and so can be used as a real-time marker of DNA amplification 
as the target sequence amplifies. Hydrolysis probes (such as those utilised by TaqMan) are 
conjugated to a fluorescent emitter (such as 6-carboxyfluorescein (FAM-reporter) and a 
quencher fluorochrome (the emitter and quencher are depicted here as blue and red circles, 
respectively). The proximity of the quencher and emitter on either end of the probe 
oligonucleotide supresses the fluorescence of the emitter even when the oligonucleotide 
anneals to the complementary sequence. As the action of Taq polymerase during extension 
phases will hydrolyse the probe oligonucleotide, fluorescence will increase with each 
thermocycle as more emitter molecules are separated from quencher molecules. 
Figure adapted from van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, 
Gabert J, van Dongen JJM. Detection of minimal residual disease in hematologic 
malignancies by real-time quantitative PCR: Principles, approaches, and laboratory 
aspects. Leukemia. 2003;17:1013-34. 
SYBR Green Hydrolysis probes 
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a single assay capable of simultaneously detecting the E. coli virulence factors eae, stx1 
and stx2 within faecal samples (14, 82). 
One of the obstacles to the use of PCR-based methodologies is PCR inhibition. As PCR 
relies upon the action of DNA-polymerases to multiply DNA sequences, and as there 
exist many biological compounds that prevent polymerases from working properly, the 
process of DNA extraction, or the removal of DNA from tissues and from the influence 
of inhibitors, is particularly important (103, 124). One of the gold standards amongst 
DNA extraction techniques is the phenol-chloroform technique, which involves 
centrifugation-mediated organic phase separation of DNA from cellular salts and 
proteins. Although the technique is prevalent in research applications for its ability to 
remove a wide range of PCR inhibitors, the toxicity of phenol and the labour-intensity of 
the protocol limits its diagnostic practicality. 
Another avenue of interest is loop-mediated isothermal amplification or LAMP, a novel 
PCR technique based on the amplification of DNA fragments at a constant temperature 
of 55-65°C through the use of six special looping primers and a DNA polymerase with a 
primer-displacing ability (89). The technique has seen some adoption in diagnostic 
settings (a LAMP platform is used to detect Clostridium difficile infections at Dunedin 
Hospital) (76), and the samples to be harvested in this project present an ideal opportunity 
to use the technique to distinguish O157 serogroups.  
The intent of the following experiments was to validate and develop a practical multiplex 
RT-PCR technique suitable for the detection of the E. coli genes eae, stx1 and stx2 (along 
with uidA as a marker of all E. coli), and to apply this in conjunction with an optimal pre-
enrichment broth to screen faecal samples sourced from Dunedin Hospital. The initial 
focus of testing was a comparison of the efficiency of four DNA extraction methods to 
determine which would be the most appropriate for the processing of faecal samples to 
be screened, with consideration for diagnostic applicability. 
A key focus in the experiments before the collection and screening of the main faecal 
samples was to determine the limit of sensitivity of the assay once the optimal pre-
enrichment broth and extraction had been selected. The test was performed on faecal 
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samples spiked with known concentrations of STEC in conjunction with a performance 
test of the pre-enrichment broth to encourage the growth of STEC with a faecal matrix. 
Attempts were made, in the interests of minimising PCR reagents costs and labour, to 
adapt the RT-PCR screening of the processed faecal samples to 384-well qPCR plates 
and to automate the loading process with the use of a robotic sample-loading platform.  
After the processed faecal samples were screened, a number of experiments were 
performed to investigate the role of PCR inhibition in a number of suspect samples.  
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3.2 Materials and Methods 
3.2.1 Probes, primers, buffers, and qPCR mix 
The sequences of four sets of custom probes and primers designed to amplify sections of 
the E. coli genes uidA, eae, stx1, and stx2 were obtained from sequences pretested by 
Nielsen et al (2003) (46). The stx2 primers were designed by Nielsen et al to detect all 
stx2 subvariants with the exception of stx2e, which does not have a significant role in 
human health. All of the primers used in the project were tested by Nielsen et al against 
GenBank sequences to ensure no ‘irrelevant’ sequences were amplified, and 
subsequently tested against a panel of enteric bacteria for specificity to E. coli by Anklam 
et al (82). The probes and primers themselves were obtained from Biosearch 
Technologies using the Custom Oligonucleotide Synthesis service (for sequence 
information, refer to Tables 4 and 5). The lyophilised probes and primers were 
individually resuspended in TE buffer (10mM TRIS buffer, 1mM EDTA, pH 7.9) to 
concentrations of 100 µM, from which working stocks of 20 µM were derived.  The 
forward and reverse primers for each gene were combined in pairs in a joint 20 µM 
working solution. All 20 µM primer and probe stock aliquots were kept at -4°C with the 
probes kept in foil to prevent UV degradation of the fluorescent dyes. Stocks (100 µM) 
were stored frozen for longer periods at -20°C. The qPCR reaction mix used for all 
reactions was PerfeCTa® qPCR ToughMixTM (2X reaction mix; Quanta Biosciences). 
The uidA probe and primer set (amplifying an E. coli-specific region of the β-
glucoronidase gene) were included in later multiplex assays as an effective internal 
amplification control and an indicator for any non Shiga-toxigenic or intimin-carrying E. 
coli in faecal testing (82). 
3.2.2 General PCR assay conditions  
For all assays prior to the main testing of faecal samples for the prevalence study, a master 
mix composed of ToughMix, and the probes and primers as required by each of the PCR-
based investigations was designed and distributed to wells of a 96-well reaction plate 
(MicroAmp® Fast Optical Reaction Plate, Applied Biosystems®). For each assay, the 
master mix was tailored such that each well reaction would total 20 µL, composed of 10 
µL (2X) ToughMix, 600 nM of each required forward and reverse primer, 200 nM of 
each required probe, and 1 µL of extracted DNA, with the remaining reaction volume 
made up with TE buffer. qPCR reactions were carried out with one of two available 
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 Gene NCBI 
GenBank 
Ref. No. 
uidA forward primer CAAAAGCCAGACAGAGTGTGATATC †  58 
94 HM221282.1 
uidA reverse primer CGGTTTGTGGTTAATCAGGAACT † 58 
eae forward primer CTCATGCGGAAATAGCCGTTA 59 
102 Z11541.1 
eae reverse primer CATTGATCAGGATTTTTCTGGTGATA 59 
stx1 forward primer GGATAATTTGTTTGCAGTTGATGTC 58 
107 Z36899.1 
stx1 reverse primer CAAATCCTGTCACATATAAATTATTTCGT 58 
stx2 forward primer GGGCAGTTATTTTGCTGTGGA 59 
130 X65949.1 
stx2 reverse primer GAAAGTATTTGTTGCCGTATTAACGA 59 
† Sequence modified from source paper (Anklam et al, 2012 (82)) using Primer Express software (Applied Biosystems; 
V2.0) for more appropriate annealing temperature   












uidA probe 5’d FAM-TCGGCATCCGGTCAGTGGCAGT-BHQ-1 3’ 70 495 nm 
eae probe 5’d Quasar 670-ATAGTCTCGCCAGTATTCGCCACCAATACC-BHQ-2 3’ 69 670 nm 








thermocyclers; an Applied BiosystemsTM Viia7 Real-Time PCR system (Life 
Technologies) utilising Applied Biosystems Viia7 software (v1.2.4), or an Applied 
Biosystems 7500 Fast Real-Time PCR system (Life Technologies) using 7500 software 
(v2.0.6). The PCR cycling parameters for reactions performed on the Viia7 system were 
as follows: a singular holding step of 50°C for 2 minutes, then a singular holding step of 
95°C for 10 minutes, followed by a cycling phase of 95°C for 15 seconds and 60°C for 1 
minute, with these two cycling temperatures repeated at these intervals for 40 cycles. The 
thermocycler used for each assay will be noted accordingly in each methodology section 
below. 
3.2.3 DNA Extraction Methods 
To remove substances from broth-based and faecal-based culture material potentially 
inhibitory to the action of DNA polymerase, four established DNA extraction methods 
were adapted.  
3.2.3.1  Boiling extraction 
The boiling extraction used is an adaption from boiling methods documented by 
Malorney et al and Walsh et al (125, 126). For any culture tested with this method, 1 mL 
of culture was dispensed to a sterile 1.5 mL microcentrifuge tube and centrifuged for 10 
minutes at 18,000 x g, before resuspension in 100 µL TE buffer (filter-sterilised with a 
0.22 µm filter). Autoclave tape was placed over the lid of the microcentrifuge tube, a 
heated syringe was used to puncture the lid of the microcentrifuge tube and the container 
was boiled in a pot cooker for 10 minutes. The sample was then cooled on ice before a 
final centrifugation step of 13,000 x g for 5 minutes. The supernatant from this final 
centrifugation was used as template DNA.  
3.2.3.2  PrepManTM extraction 
The PrepManTM (Applied Biosystems) kit based extraction was performed as per the 
manufacturer’s instructions with minor modifications to the volumes used. For the 
culture prepared with this method, 0.2 mL was dispensed to a 2 mL microcentrifuge tube 
and the sample was centrifuged for 3 minutes at 16,000 x g. The supernatant was 
discarded and 200 µL of the PrepMan Ultra Sample Preparation Reagent was added to 
the tube and the tube mixed on a vortex mixer for 10-30 seconds. The sample was then 
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heated in a pot cooker for 10 minutes at 100°C and centrifuged for 3 minutes at 16,000 x 
g, with the supernatant used as template DNA. 
3.2.3.3  Phenol-chloroform extraction 
The phenol-chloroform method documented here is adapted from Sambrook et al (127), 
with initial washing steps derived from Giraffa et al (128), centrifugation speeds based 
on recommendations from Zoetendal et al (129), and alcohol precipitation steps as 
described by Hoff-Olsen et al (130). For each sample extracted by the phenol-chloroform 
method, 1 mL of culture was washed twice by centrifugation at 12,000 x g and 
resuspended in 1 mL PBS or TE buffer. The sample was then centrifuged at 12,000 x g 
before resuspension in 500 µL of a TE extraction buffer (10mM TRIS, 2.5mM EDTA, 
0.5% SDS, 100mM NaCl, 100 µg mL-1 proteinase K, pH 7.9). The resuspended sample 
was then incubated in the TE extraction buffer for 1-2 hours in a 56°C water bath before 
the addition of 500 µL of 25:24:1 phenol-chloroform-isoamyl alcohol solution (Sigma-
Aldrich®) to each sample tube. Each sample was forcefully inverted by hand until a milky 
emulsion formed. Each sample was then centrifuged at 14,000 x g for 5 minutes. The 
aqueous upper layer of the separated phases was extracted by pipette and transferred to a 
new microcentrifuge tube, taking care to avoid drawing up the proteinaceous interface or 
the lower organic phase. The sample was then mixed with 500 µL of pure chloroform 
with a repeat of the centrifugation and phase separation of the phenol-chloroform step. 
The DNA of each sample was precipitated adding NaCl to a concentration of 0.2M based 
on the net weight of the sample and mixing by gentle pipette aspiration. Chilled ethanol 
(100%; 1 mL) was added to each precipitate and the mixture was centrifuged at 14,000 
x g before removal of the ethanol supernatant by pipette. This ethanol washing step was 
repeated with 1 mL of 70% ethanol with each sample before the samples were left open 
in a fume hood for 30 minutes to facilitate evaporation of the last of the ethanol. Each 
sample was resuspended in 30 µL of RNAse-free water except where documented. 
Extracted samples were kept at -4°C or -20°C for longer storage.   
3.2.3.4  Chelex-100 extraction 
The Chelex-100 method described is adapted from the method as described by Malorney 
et al (125). For each sample processed using this method, 1 mL of culture material was 
transferred to a 1.5 mL capped microcentrifuge tube and centrifuged at 10,000 x g for 10 
minutes. The supernatant was discarded and the pelleted material was resuspended in 300 
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µL of a 6% weight-to-volume suspension of Chelex-100 resin in Milli-Q (filtered, de-
ionised) water. The suspension was incubated at 56°C in a water bath for 15-20 minutes 
before vortex mixing for 5 seconds and a further incubation at 100°C for 8 minutes on a 
heating block. Each sample was then chilled on ice for 2 minutes and centrifuged at 
14,000 x g for 5 minutes, with the supernatant from this final centrifugation used as 
template DNA. 
3.2.4 PCR validation assays and amplification efficiency check 
To ensure that the PCR probes, primers, PCR mix and thermocycler conditions selected 
were capable of reproducible and efficient DNA amplification of the target sequences, 
an overnight 37°C TSB culture of each of the E. coli strains O111:K88:H-, O91:H-, and 
O130:H11 was processed with the phenol chloroform method as described above. The 
concentration of the extracted DNA was determined through UV spectroscopy (DNA-50 
function with NanoDrop 1000 v3.7.1, Thermo-Fisher Scientific), and diluted with TE 
buffer based on these readings to a concentration of 1 ng µL-1. Each of these samples was 
diluted serially ten-fold in TE to give a 5-order-of-magnitude log10 standard of template 
DNA for each of the gene assays. Four individual PCR assays were set up using the 
standard PCR conditions (outlined above) for the Applied Biosystems Viia7 
thermocycler. Using the log10 standard of each of the DNA templates and the standard 
PCR conditions (outlined above), a standard curve was constructed for each of the genes. 
Each of the assays had a custom master mix containing only the probe and primer set of 
the genes each E. coli strain was expected to contain (a uidA and eae assay with an 
O111:K88:H- log10 DNA standard, an stx1 assay with an O91:H- DNA log10 standard, 
and an stx2 assay with an O130:H11 log10 DNA standard). Each well of each assay had 
1 µL of each of the log10 dilutions of DNA template added and each dilution was assayed 
in triplicate. A well to which no template DNA was added was included with each assay 
to act as a negative amplification control. A cursory check of eaeA, stx1 and stx2 
specificity was also performed at this time; each of the primer sets was tested individually 
with STEC strains mentioned in this section that lacked the corresponding gene to rule 
out non-specific or off-target amplification. 
To ensure that the target sequence of each assay was amplifying efficiently, the Applied 
Biosystems Viia7 software was used with the data of the log10 DNA standards mentioned 
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above to calculate a standard curve based on the cycle threshold (Ct) values of each of 
the assays, from which the amplification efficiency could be calculated. 
3.2.4.1  PCR amplicon size check 
To verify that the primers described in Table 4 were amplifying the correct sequence 
fragments as predicted by Primer Express software, each of the probe and primers sets 
of the multiplex were prepared in separate PCR mixtures and used to amplify the 
predicted sequences from a phenol-chloroform extracted overnight TSB culture of 
O84:HNM. The DNA extracted (5 µL) by each assay was combined with 5 µL of 
bromophenol blue loading dye and run on an electrophoretic 2% agarose gel (SeaKemp® 
LE agarose, Lonza) with ethidium bromide added at a concentration of 50 µg mL-1. The 
DNA samples were run alongside molecular ladders and a negative control composed of 
a post-PCR mix with no added template. 
3.2.4.2  Multiplex amplification efficiency check 
A comparative amplification efficiency check was completed to ensure that none of the 
individual assay amplification efficiencies would be significantly affected by 
multiplexing. Using new master mixes containing combinations of each of the probe and 
primer pairs, a DNA standard was constructed using standard PCR conditions under the 
same conditions used for the initial PCR validation. The samples’ dilutions were 
distributed in triplicate in the same manner as the individual assays, but instead of only 
adding one DNA type, 1 µL of each of the O111:K88:H-, O91:H-, O130:H11 dilutions 
were added to each reaction well (the master mix had a reduced amount of TE buffer so 
that each well volume would still sum to 20 µL) so as to provide a DNA template for all 
of the assays in the multiplex. The probe and primer sets were tested sequentially, adding 
eae, stx1, and stx2 to a uidA reaction in separate assays to see if any one reaction 
interfered notably with the others.  The software of the Applied Biosystems Viia7 was 
then used to generate a standard curve for each of the assays within the complete 
multiplex reaction. The reaction efficiencies were then compared to the reaction 
efficiencies of the individual assays. A software-generated standard curve for each of the 
assays within the multiplex can be viewed in the results section. As with the individual 
assays, wells with all of the reaction components but no template were included as 
amplification negative controls. 
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3.2.5 PCR extraction method yield comparison 
3.2.5.1  Relative DNA yield by cycle threshold values 
To compare the efficiency of the extraction methods in extracting DNA, a TSB culture 
of O111:K88:H- was incubated at 37°C for 6 hours and extracted by each of the extraction 
methods detailed above (boiling, PrepMan, phenol-chloroform and Chelex-100). To 
ensure consistency, each of the extraction methods was conducted on the same 
O111:K88:H- culture which was kept chilled on ice (4°C) between each extraction. As 
the PrepMan method involved a smaller amount of culture to be processed compared to 
the other DNA extraction methods used (0.2 mL as opposed to 1 mL), appropriate 
dilutions of each of the extracted samples were carried out in TE buffer to account for 
the unequal volume extracted. The extracted material was applied to a qRT-PCR assay 
in triplicate wells with a master mix composed of only the uidA probe and primer set. 
The cycle threshold (Ct) values were then compared across the samples that had been 
processed by each of the four extraction methods to determine the most efficient form of 
DNA extraction. An uninoculated culture was processed with the four extraction methods 
alongside the live culture and included in the subsequent qRT-PCR assay as a functioning 
amplification control.  A comparison of DNA yield by direct DNA spectroscopy was 
avoided as some proteinaceous compounds not removed by Chelex-100 were recognised 
to interfere with such readings (131).   
3.2.5.2  Gel photos of extracted DNA 
To examine the physical state of the extracted template DNA generated by the four 
extraction methods, an O91:H- TSB culture incubated for 6 hours was extracted by the 
boiling method and Chelex-100 method, while another O91:H- TSB culture was 
similarly incubated for 6 hours was extracted by the phenol-chloroform and PrepMan 
methods. The DNA extracted (5 µL) by each method was combined with 5 µL of 
bromophenol blue loading dye and run on an electrophoretic 0.7% agarose gel 
(SeaKemp® LE agarose, Lonza) with ethidium bromide added at a concentration of 0.5 
µg mL-1. The DNA samples were run alongside molecular ladders and negative controls 
composed of uninoculated TSB cultures that were processed alongside each of the 
extracted cultures. TRIS pH 7.0 was used as a running buffer. 
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3.2.6 PCR-based quantitation 
To accurately estimate the number of STEC CFU in the prepared standards for use in 
determining multiplex sensitivity and possibly the CFU mL-1 of faecal specimens, a 
survey of the genome sizes of stx+ and stx- E. coli was conducted using the E. coli 
Genome Assembly and Annotation Report table on the NCBI database (Available at 
http://www.ncbi.nlm.nih.gov/genome/167 under the tab labelled “Genome Assembly 
and Annotation Report”). Using the table feature to sort all of the catalogued sequences 
by ‘level’ (how complete the archived sequence was), all of the available complete E. 
coli FASTA sequences were imported and analysed using pDRAW software (pDRAW32 
1.0, revision 1.1.121; ACACLONE software, available at http://www.acaclone.com). 
Using the “find sequence” function, a search was run on the four probe sequences (as 
featured in Table 4) to distinguish STEC genomes from non-STEC genomes and to 
enumerate copy numbers of each sequence. Each sequence search permitted up to 3 base 
pair mismatches. The genome sizes (as recorded on the Genome Assembly and 
Annotation Report table) for STEC and a sample of non-STEC were then separately 
pooled and graphed using PRISM software, from which the average and median could 
be calculated. Calculations based on the molecular weight of DNA molecules in 
conjunction with the mean STEC genome size were used to arrive at a representative 
weight per STEC genome. With the weight of a representative STEC genome known it 
was possible to relate the number of genomes by weight to the concentration of DNA in 
an extracted sample (assessed as ng µL-1 through NanoDrop readings of phenol-
chloroform extracted E. coli cultures) through to Ct values when a known concentration 
of DNA was amplified. A standard curve of estimated numbers of genomes per well 
could be then constructed and used on qRT-PCR plates to estimate the number of STEC 
genomes in other wells. 
3.2.7 Use of faecal specimens 
In accordance with the New Zealand Human Tissues Act 2008 and the New Zealand 
Health Information Privacy Code 1994, a protocol was devised to source the faeces and 
pertinent personal information regarding the patients involved in a manner that would 
not infringe upon the patient’s right to privacy of health information. In brief, faecal 
samples that satisfied the selection criteria sourced from the health agency (SCL) were 
to be collected and labelled with a unique identifier (SCL’s internal identification 
number) and with the donor’s age status (a binary status of ≥12 years of age or younger) 
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and whether the donor was registered as an inpatient or outpatient at the time of 
collection. Only this information was to be provided by SCL staff, with no other personal 
information provided to the researcher. Ethics committee approval was obtained through 
designing the collection of faecal samples so as to comply with exception (e)i of the 
Health Information Privacy Code 1994 Rule 10 (Limits on the use of health information) 
which states “[health records may be used] for statistical or approved research purposes 
provided [the] information is not published in a form that could reasonably be expected 
to identify the individual”. The acquisition of informed consent of the patients from 
whom the samples were sourced was deemed unnecessary on the basis of the Human 
Tissues Act 2008 Section 20 (e), which states informed consent is not required for 
collection or use of “the carrying out, by using for a secondary purpose tissue that is a 
body or is collected from a living individual or a body, […] of research that has received 
the approval of an ethics committee […]”. An explication of other relevant sections of 
the Code and the Act as provided on request of further clarification to the University 
Ethics Committee can be found in Appendix 2. For a flowchart detailing the collection 
of samples that was also provided to the Ethics Committee, see Figure 10. 
3.2.7.1  University of Otago Ethics Committee Approval 
In compliance with the University of Otago Human Ethics Committee’s policies on the 
acquisition and use of human tissue(s) for research, an application for Human Ethics 
Committee (Health) Departmental Approval of Projects using Health Information was 
completed (see Appendix 3 for a copy of this document and a copy of SCL approval) 
prior to work with faecal specimens commencing. For documents relevant to University 
of Otago Ethics Committee and their approval, please refer to Appendix 2. 
3.2.7.2  Maori Affairs Consultation 
In agreement with the New Zealand Human Tissue Act 2008 Section 18 and the 
University’s policy regarding consultation with Māori, a discussion with the Ngāi Tahu 
Consultation Committee was completed to ensure the project was compliant with Tikaka 
(“best practice”; a concept which encompasses respect, collection, retention, and return 
of the body parts or genetic material of Māori, usually on spiritual grounds). The use of 
faeces in the manner proposed for the project was deemed appropriate by the committee 
as Māori did not desire return or especial retention of faecal material or derivatives on 
spiritual grounds. A copy of the Ngāi Tahu Consultation Committee document can be 
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SCL continuously receives stool samples from community 
and hospital. 
Figure 10. Flowchart of the collection and processing of faecal specimens during the 
main collection phase  
(4 July 2014 – 8 August 2014) 
Samples defined as diarrhoeic (stools that take the shape 
of the container) are selected. 
SCL staff use each sample to inoculate an individual 
enrichment broth provided by the researchers. The 
containers are only labelled with age, in/out patient 
status and a unique ID assigned by SCL. 
The researcher obtains the inoculated enrichment broths 
and incubates to encourage the growth of bacteria. 
The culture is processed to extract and purify the DNA for 
use with molecular assays. 
Extracted DNA is frozen for long term storage. 
Once enough extracted DNA is amassed, all of the 
extracted DNA to date is processed together in a large 
batch. This assay only examines bacterial (STEC) DNA. 
After a defined time period (likely to be a 3 month catchment 
period) the data will be compiled by the researcher and used 
to make conclusions as to the prevalence of the organism in 
the samples. 
At the conclusion of the study, the data will be shared 
with SCL and it is expected SCL will determine whether 
the assay and/or data is of retrospective clinical or 
diagnostic relevance in combination with patient 
information that only they are privy to. 
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found in Appendix 4, along with the pertinent sections of the Southern District Health 
Board’s Tikaka Best Practice document. 
3.2.7.3  Containment, handling and disposal 
A SOP was researched and developed to ensure proper conduct, including the use of 
Personal Protection Equipment (PPE) and containment facilities. A copy of this 
document is included in Appendix 1 and was incorporated as a physical copy with the 
University safety documentation in the laboratory. 
3.2.7.4  Selection criteria and storage of live specimens 
As there remains no standardised definition of diarrhoea, diarrhoeal stool specimens were 
selected from amongst the samples submitted to SCL on the basis of visual sample 
viscosity. Samples of a loose consistency that were noted to ‘take the shape’ of their 
parent container under their own weight were regarded as diarrhoeic and included in the 
study. 
As some experimentation with faecal material required the storage and retention of live 
specimens, approval to store live specimens on site in a -80°C freezer in cryobroth (Fort 
Richard laboratories) was obtained from SCL. 
3.2.8 Stationary phase O84:HNM growth curve 
For qPCR assay sensitivity testing, an 18 hour growth curve of O84:HNM was carried 
out to determine when this strain reached stationary phase. The intent of the growth curve 
was to ensure that reasonably accurate CFU mL-1 dilutions could be made from stationary 
phase cultures but without the discrepancy between OD600nm reads and CFU mL
-1 that 
was likely to occur in the strain’s death phase. For this experiment, two 20 mL Universal 
bottles containing 10 mL of TSB were inoculated from a single colony of O84:HNM 
grown on TSA overnight at 37°C. The cultures were well mixed, and the OD600nm of these 
were read using 100 µL in triplicate wells of a 96-well microtitre plate with the Varioskan 
plate reader. These two Universal bottles were incubated in a 37°C incubator under 
aerobic conditions. One of these Universal bottles was mixed by pipette aspiration and 
100 µL of culture was dispensed for OD600nm reads in triplicate on the hour for 9 hours, 
and then three hourly until 18 hours. The second Universal bottle was dispensed and read 
in the same manner with mixing only every 3 hours. The OD600nm reads, normalised 
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against an averaged TSB blank, were charted using Microsoft Excel 2013 and Prism 
software. This protocol also provided information on the growth dynamics of a Universal 
bottle E. coli monoculture with and without hourly agitation.  
3.2.9 Preliminary Faecal screening 
To ensure that faecal specimens to be used in subsequent faecal spiking assays did not 
have endogenous STEC, several diarrhoeic specimens were selected at SCL and 1 mL of 
faeces was used to inoculate 9 mL of TSB, with 16 mL of faeces frozen at SCL at -80°C 
in 4 mL of cryobroth (Cryo Broth, Fort Richard Laboratories). The TSB culture was 
taken back to the University laboratory and 1 mL was extracted with Chelex-100 and 
subjected to the general PCR conditions on the Applied Biosystems 7500 thermocycler 
described above. Samples that tested negative for any of the pathogenic genes were used 
for spiking experiments as outlined below. As with all assays involving faecal specimens, 
reaction wells with no template were included as negative controls.  
3.2.10 Multiplex sensitivity testing by faecal spiking 
To determine the limit of sensitivity of the multiplex to detect each of the pathogenic 
(eae, stx1, stx2) genes in a faecal specimen, and the changes to faecal STEC populations 
rendered by 3 hours of incubation in nonselective TSB, a protocol to grow and spike 
faecal samples was developed. An overnight culture of E. coli O84:HNM was grown in 
TSB at 37°C and the CFU mL-1 determined through OD600nm reads. Once calculated, the 
culture was diluted in sterile TSB to a concentration of 2 x 105 CFU mL-1. This culture 
was then serially diluted ten-fold in sterile broth to give a dilution series down to 
(theoretically) 2 CFU mL-1. An unspiked control was included. Two faecal samples 
(referred to as β and γ) that had tested negative for endogenous STEC were thawed from 
-80°C and 1.25 mL (to compensate for the dilution in cryobroth) was distributed to 
multiple 20 mL Universal bottles containing 7.75 mL of sterile TSB. The O84:HNM 
dilution series (1 mL of each) was then added to spike the faecal samples. The spiked 
samples were well mixed and 1 mL of the spiked mixture was extracted by the Chelex-
100 method (a 0-hour sample), while the remainder of the spiked samples were incubated 
for 3 hours at 37°C under aerobic conditions. The samples were again mixed, and another 
1 mL of the same cultures were then extracted by the Chelex-100 method. The extracted 
specimens were then tested in triplicate using the complete multiplex under the general 
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PCR conditions on the 7500 thermocycler alongside a phenol-chloroform extracted 
O84:HNM DNA standard. 
A similar protocol using the same faecal samples (β and γ) and the same spiking method 
was also completed, with the differences being that the samples were spiked with an 
exponential-phase O84:HNM culture (incubated for only 6 hours) and each sample was 
extracted with both the phenol-chloroform and Chelex-100 extraction methods with no 
incubation phase. The extracted DNA samples were tested with the multiplex PCR assay 
in duplicate on the 7500 thermocycler under general PCR conditions alongside a 5 log10 
phenol-chloroform extracted O84:HNM DNA standard. This protocol was intended to 
investigate any differential effects of growth phase or extraction method in comparison 
to the protocol above. 
3.2.11 Enumeration of spike replicate 
To better understand growth characteristics seen in the faecal spiking experiment, the 
experiment was replicated without added faeces (see section 3.3.7). A O84:HNM TSB 
culture was incubated for 17 hours at 37°C, enumerated by OD600nm readings, and diluted 
to 2 x105 CFU mL-1 and diluted ten-fold as in the spiking experiment. A 0.1 mL volume 
of each spike diluted was plated to TSA (effectively a 0-hour sample) and incubated at 
37°C overnight under aerobic conditions. The spiked broths were incubated for 3 hours, 
mixed, and then 0.1 mL volume was plated to TSA and incubated overnight at 37°C under 
aerobic conditions. For both sets of plates, a ten-fold and one-hundred-fold dilution of 
the 105 and 104 spikes and the broths incubated for 3 hours with the 105 and 104 spikes 
were plated, in case of innumerable colony counts. The spike and post-incubation broth 
were enumerated by colony counts on the TSA plates by colony counts of plates that had 
between 20-250 colonies. The intent of this experiment was to check whether the E. coli 
O84:HNM growth curve was accurate during the strain’s stationary phase and to provide 
information on the growth of the strain during 3 hours of incubation in the absence of 
faeces. 
3.2.12 Plate counts, NanoDrop readings and calculated Ct values comparison 
To check for potential discrepancies between NanoDrop readings, genome estimates 
calculated by Ct values, and CFU plate counts, 3 x 10 mL TSB cultures were inoculated 
with O130:H11, grown for 6 hours under aerobic conditions and 1 mL subjected to 
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phenol-chloroform based DNA extraction. The same cultures were also serially diluted 
ten-fold in sterile PBS and 0.1 mL of a 1 x 10-7 dilution of the culture was plated to TSA 
and incubated overnight at 37°C under aerobic conditions for plate counting. Plates with 
between 20-250 colonies were used to generate CFU estimates. The CFU mL-1 as 
calculated from the plate counts, the UV spectroscopy readings, and the genome 
estimates of the extracted DNA as calculated from Ct values derived from the Applied 
Biosystems Viia7 thermocycler were compared. 
3.2.13 ROX-inclusive master mix validation 
In light of a recurring algorithmic correction problem with some assays involving the eae 
probe and primer set, a test utilising an alternate PCR mix (TaqMan Universal Master 
Mix II with UNG, AB Biosystems) was constructed. As the general mix was also a 2X 
solution, the experiment simply called for the substitution of ToughMix with Universal 
Master Mix in the same multiplex and thermocycler parameters. ROX-correction is a 
default setting on Applied Biosystems Viia7 and 7500 software. The wavelength for the 
endogenous dye was 610 nm. This experiment was completed on the Viia7 thermocycler, 
using a phenol-chloroform extracted faecal sample that was found to have had 
endogenous levels of stx1+ and/or stx2+ bacteria in a previous test, and while likely 
negative for eae, was typical of an anomalous pattern of eae fluorescence sometimes read 
by the Viia7. As well as testing whether endogenous dye normalisation would correct the 
anomalous reading, the test would also be able to demonstrate that the dye could work 
without impeding the multiplex reaction when testing a faecal-derived specimen.  
3.2.14 Collection and processing of faecal samples to be used in main prevalence 
assay 
The faecal specimens (n = 522) used in the main assay were collected from the 
Microbiology section of SCL, Dunedin Hospital, from the 3rd of July 2014 to the 7th of 
August 2014. The specimens were all of the samples tested by SCL for common faecal 
pathogens (refer to Table 6 for common faecal pathogens tested for at SCL, Dunedin 
Hospital) on each day of the period and which met the selection criteria for diarrhoeic 
stools. Each day’s worth of specimens was collected for the project 24 hours after SCL 
testing (live faecal specimens were retained on site for up to a week after SCL testing). 
Samples collected by SCL staff over the weekends were collected for the project on the 
ensuing Monday. A 20 mL Universal bottle containing 9 mL of TSB was inoculated with 
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TABLE 6: Faecal microbiology tests conducted at SCL, Dunedin Hospital 
 
Bacteria 
Salmonella, Shigella, Campylobacter, Yersinia spp, O157:H7, Clostridium difficile, Aeromonas spp, Pleisomonas 
spp 
Parasites Giardia, Cryptosporidium, Dientamoeba fragilis, Blastocystis hominis, Isospora or Cycospora cysts 
Viruses Rotavirus 
Special test requests Faecal calprotectin, H. pylori 
Faecal panel testing may also include checks for cells, cysts and nematodes under microscopy as indicated 
50 
 
1 mL of each faecal sample on site, and the approved information (patient age category, 
in patient status) for each sample was accessed by SCL staff. The date at which SCL had 
received each sample was also recorded. Each of the samples were extracted from the 
SCL testing container using 1 mL pipette with tips that had the end of the tips sliced off 
with a hot razor to widen the bore. Each sample was well stirred before removal, and an 
estimate of volume was made for samples from which less, or much less than 1 mL of 
faecal material could be obtained. The inoculated TSB cultures were kept on ice (-4°C) 
during transportation to the University laboratory, where they were immediately 
incubated for 3 hours at 37°C under aerobic conditions. After incubation, 1 mL of each 
faecal culture was extracted using the Chelex-100 DNA extraction method and frozen at 
-20°C in 1.5 mL microcentrifuge tubes. For the duration of the collection period, other 
faecal samples (n = 50) that were specifically tested for the presence of H. pylori (but 
separate from the main battery of tests) and that met the selection criteria were also 
collected. Samples scheduled for H. pylori testing were held at SCL and tested weekly 
on a Thursday, and so a week’s worth of H. pylori samples were collected by the 
researcher on a Friday. On the 31st of July 2014, the researcher noted faecal specimens 
that were scheduled for faecal calprotectin assays at SCL could also be of relevance to 
the project, and so specimens scheduled for faecal calprotectin assays from this date that 
met the inclusion criteria (n = 26) were also included. As the final day of the collection 
period was a Friday, effectively two weeks’ worth of samples scheduled for faecal 
calprotectin assays were collected. 
3.2.15 384-well plate validation assay 
To make the testing of the faecal DNA as economical as possible with the use of a 384-
well robot plate loader, an assay to ensure that the multiplex could be successfully 
downscaled to 10 µL-well 384 well qPCR assay plates and still be detectable on the Viia7 
thermocycler was performed. Custom master mixes retaining the optimal probe and 
primer concentrations and 1 µL of extracted DNA sample but with reduced ToughMix 
(5 µL in each 10 µL well as opposed to 10 µL in each 20 µL well on a 96-well plate) and 
water volume (volume summed to 9 µL as opposed to 19 µL) were composed and assayed 
on a 384-well qPCR plate using the Viia7 thermocycler.  
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3.2.16 Main faecal assays 
3.2.16.1 Robot-Loaded 384 plate assays 
To load the 384 well plate, a VERSA Aurora 110 Workstation (Appl. 110; Aurora 
BioMed Inc.) was used utilising v1.0.67 software on a desktop running Windows XP. To 
have the robotic platform load the 384-well plate, it was necessary to thaw and transfer 
50 µL of each of the faecal extracts from the microcentrifuge tubes in which they were 
stored at -20°C to empty 96-well plates that could be inserted on the platform. An initial 
test of the robot loader with optimised conditions (optimised primer concentrations of 
800 nM for uidA, 600 nM for eae, stx1 and stx2 primers, and optimised probe 
concentrations of 200 nM for uidA, 300 nM for eae, and 120 nM for both stx1 and stx2 
probes), an O84:HNM DNA standard and select faecal samples as a test of function was 
first completed. For the subsequent large scale testing of the faecal samples for the 
prevalence study, two 96-well plates, one containing 96 samples and another containing 
89 samples plus a 7 point DNA standard (containing 100, 10, 1, 0.1, 0.01, 0.001 and 
0.0001 ng µL-1 phenol-chloroform extracted O84:HNM) were loaded on the platform. 
The robot loader was programmed to distribute 9 µL of a pre-made master mix suited to 
384 well assays to each well of the 384-well plate, followed by 1 µL of each of the 
extracted DNAs to two wells each of the 384 well plate along with the standard. Due to 
the large volume to be dispensed, master mixes with an extra 10% of required volume 
were used to prevent any discrepancies in pipette tip dispensation leading to a shortfall 
in master mix.  The programme called for a 200 µL tip to be used to dispense the master 
mix and a tip change was programmed to occur after half of the wells on the plate were 
filled with master mix. The extracted DNA samples were dispensed using 20 µL pipette 
tips with a tip change between each sample. The loaded 384 well plate was then assayed 
on the Viia7 thermocycler using the standard cycling conditions with the reaction volume 
set to 10 µL on the Viia7 software. The results required a repeat of the protocol and 
loading programme with a limited number of samples. A troubleshooting follow up test 
was then completed which involved programming the robot to dispense 9 µL of a viscous 
solution (glyercol added to water at the approximate viscosity of ToughMix) in a similar 
manner to a 384-well plate followed by adding 1 µL of bromophenol blue dye as a test 
of robot dispensation. A reattempt of the first 384-well assay with most of the same DNA 
samples and standard as above, but with slightly different properties and protocol was 
then completed. In this attempt, the master mix was made with an extra 15% volume on 
top of projected well volume requirements. The loading protocol was adjusted to increase 
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the number of 200 µL pipette tip changes during master mix dispensation to 5 per plate, 
and to change the amount loaded to 8 µL per well. During the sample loading stage, the 
amount of sample to be dispensed was adjusted to 3 µL and a mixing step consisting of 
three short aspirations in the master mix in each well for each sample was added.  
3.2.16.2 Validation of reduced volume 96-well assay 
Due to problems with robot loading, and in an attempt to reduce reagent cost of the main 
assay, an assay to validate further assays of faecal samples using 96-well plates with a 
reduced volume of ToughMix was completed on the Viia7 thermocycler. This assay was 
like the 96-well assays that had preceded experimentation with the 384-well plates, but 
with half the amount of reagents used per well; 5 µL of ToughMix, the optimised probe 
and primer concentrations, 1 µL of select DNA samples (extracted O84:HNM and select 
DNA samples from amongst the faecal extractions) and TE to sum the reaction volume 
to 10 µL per well. 
3.2.16.3 Remainder of main assay testing 
The remainder of untested faecal DNA samples and samples for which the assays had 
failed in the second attempt of the 384-well format were assayed in duplicate over 13 x 
96-well qPCR plates with the optimised probe and primer concentrations (although non-
optimal concentrations of 200 nM were used for the uidA probe, 600 nM for the eae 
primer and 300 nM for the eae probe), reduced reagent volumes (10 µL) and with 
standard cycling conditions on the 7500 thermocycler (it should be noted it was the intent 
of the researcher to use the Viia7 thermocycler for all of the main assays for consistency, 
but the Viia7 was out of service following the 384-well experimentation). Each of the 
96-well plates had 8 wells reserved for positive controls in duplicate and two wells to 
which no DNA was added to function as a negative control. The positive controls 
consisted of four wells of phenol-chloroform extracted O84:HNM (two wells with 1 ng 
and two wells with 0.1 ng), and three “clinical” controls over six wells (two wells with a 
faecal sample that had tested stx1+, stx2+ in previous testing (denoted sample #36), two 
wells dedicated to a eae+ faecal sample (sample #89), and two wells to a clinical negative 
or uidA+ only faecal sample (sample #50)). Overall prevalences of stx+ and eae+ E. coli 
amongst the samples processed were computed with 95% confidence intervals (CI) by 
Stata software (StataCorp. 2013. Stata Statistical Software: Release 13.1 College Station, 
TX: StataCorp LP). 
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3.2.17 PVPP column testing 
3.2.17.1 Initial test of PVPP processing of faecal samples and BSA assay 
Due to some of the results in the main assay having no or poor amplification of the uidA 
gene, initial testing with polyvinylpolypyrrolidone (PVPP) columns to determine if this 
was a practicable solution to eliminate potential inhibition in the samples was completed 
using selected samples from the assays. The PVPP columns (Zymo-Spin™ IV-HRC 
Microcentrifuge tubes; Catalogue no. C1010-50) were used according to an adaption of 
the manufacturer’s instructions provided in step 11 of the ZR fecal DNA MiniPrepTM 
Instruction manual provided by Zymo Research. The PVPP columns were prepared by 
breaking off the tabs below the column and centrifuging the incumbent aqueous solution 
into a collection tube at 9,000 x g for 3 minutes. For each of the (four) selected samples, 
50 µL was deposited into the columns, the caps reapplied and centrifuged again at 9,000 
x g for 2 minutes into clean 1.5 mL microcentrifuge tubes. The processed samples were 
then tested with only the uidA probe and primer set in duplicate using the Viia7 with 
standard cycling conditions and concentrations (200 nM of probe and 800 nM of primer) 
with reduced (10 µL) well volumes on a 96-well plate. The processed samples were tested 
alongside the same DNA samples before PVPP processing to see if there was any 
apparent improvement rendered in fluorescence or Ct value. A separate master mix 
identical to the others but incorporating 0.1mg mL-1 bovine serum albumin (BSA) was 
also included on the same plate.  A similar test with a 96-well Silicon-A-HRC 
purification plate (Zymo Research; Catalogue no. C2009) was completed to determine if 
this item could be used to PVPP-process multiple samples efficiently, rather than to 
purchase and use an individual PVPP column (Catalogue no. C1010-50) for each sample. 
For the 96-well Silicon-A-HRC plate protocol, a method based on steps 9 and 10 of the 
online protocol for the product (available from 
http://www.zymoresearch.com/dna/microbial-environmental-dna-isolation-1/soil-fecal-
plant-dna/zr-96-fecal-dna-kit under the ‘Protocol’ tab) was adapted for use with the 
sample. For each of the samples to be tested (a selection of prevalence study samples and 
O84:HNM phenol-chloroform extracted DNA), the foil cover of the wells on a Silicon 
plate were removed, and 100 µL of TE buffer were added to each well. The Silicon plate 
was placed over a catchment 96-well plate and the assembly was centrifuged at 1, 470 x 
g for 5 minutes. An error with the protocol occurred where the buffer that was used to 
elute the Silicon plate was not removed from the collection plate beneath before 50 µL 
of the samples to be processed were added to the Silicon plate and the assembly 
54 
 
centrifuged at 2, 250 x g for 6 minutes. It was decided to proceed with DNA amplification 
as the elution TE buffer was not expected to inhibit the reaction. The processed samples 
were assayed on the Viia7 thermocycler under standard conditions in a 384-well qPCR 
plate. 
3.2.17.2 Main PVPP processing and retesting of questionable samples 
All of the samples suspected of potential inhibition, that is, those that had either no 
amplification of one or both of their duplicate assays or returned very high Ct values 
were processed with PVPP columns and retested with the 7500 thermocycler. The PVPP 
columns (Catalogue no. C1010-50) were prepared as in initial testing and a portion (50 
µL) of the samples that showed poor amplification were centrifuged at 9,000 x g for 2 
minutes. These samples were then processed using the standard conditions and optimised 
probe and primer concentrations on the 7500 thermocycler with 1 µL of processed 
template DNA. The Ct values were compared against the values attained for each sample 
during the main assays to determine if and how many samples had putatively inhibitory 
substances removed by the PVPP processing. 
3.2.17.3 Internal amplification testing of selected PVPP-processed samples 
Due to many amplification results showing little change post PVPP processing, it was 
decided to conduct an internal amplification assay of selected post PVPP-processing 
samples to determine if the poor results seen were a result of inhibitory substances that 
may not have been successfully removed by PVPP processing. For this assay, a selection 
of samples that showed poor amplification and a slight degradation of uidA Ct with PVPP 
processing (samples #321, #322, #331, #333), samples that had no amplification 
whatsoever and no change with PVPP processing (#362, #369, #376) and samples that 
showed low amplification with no change with PVPP processing (#485, #504) were 
assayed on the 7500 thermocycler with standard (reduced volume) conditions with an 
internal amplification plasmid (pChook IAC). The processed samples were to be tested 
against a negative control without DNA added, to examine whether there was any 
discernible inhibition remaining after PVPP processing. The assay also included portions 
of each of the same DNA samples not yet processed with PVPP columns to putatively 
examine whether there was any change in inhibition seen with PVPP processing. The 
samples were tested alongside extracted DNA retained from the faecal spiking 
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experiments functioning as positive controls, and wells with no template added were 
included as amplification controls. 
3.2.18 LAMP based detection of O157 serotypes 
An OptiGene Loop Mediated Isothermal Amplification (LAMP) assay was used to 
distinguish between O157 and non-O157 serogroups amongst the samples found to be 
positive in the prevalence study. The assay was also tested with a number of samples 
with dubious positivity (usually very high Ct values of one of the pathogenic genes seen 
in one of the duplicate wells of a sample). This LAMP assay called for the use of an 
alternate master mix (Isothermal Master Mix, OptiGene Ltd.) and alternate primers (F3 
and B3, LoopF and LoopB, FIP and BIP) intended to target the O157 specific gene rfbE, 
designed through the use of Primer Designer Software (v1.13; PremierBiosoft) and 
manufactured by Sigma’s oligonucleotide synthesis service (for LAMP primer 
information, refer to Table 7). The format of samples tested with LAMP was as according 
to the manufacturer’s recommendations of 15 µL of Master Mix, 5 µL of Primers, and 5 
µL of sample template per reaction. The concentration of the primers in each reaction 
were 5 pM each of F3 and B3, 10 pM of LoopF and LoopB, and 20 pM of FIP and BIP. 
The reaction parameters recommended the use of an OptiGene Genie II assay platform 
for thermocycling conditions, but as this was temporarily unavailable, the reactions were 
first attempted on the AB Biosystems Viia7 thermocycler with similar conditions. For 
the Viia7, each of the samples to be tested were placed into a 96-well qPCR plate and 
subjected to the following conditions; 65°C for 60 minutes, followed by an annealing step 
of 98°C for 2 minutes with temperature ramping of 1.6°C/s. As the master mix contains 
only SYBR green fluorescent dye, the Viia7 was set to read SYBR green fluorescence 
only. The reaction well volume was set at 20 µL per well. On the Genie platform, the 
master mix, primers and samples were prepared as described above and were loaded into 
provided custom tubes and placed in slots on the top of the instrument. The assay 
conditions were 65°C for 30 minutes followed by a single annealing step of 98°C with 
ramping at 0.1°C per minute. As there were issues with transferring the data from the 
platform to the included software on the researcher’s computer, screenshots of the 
relevant results are provided in the results section.  
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TABLE 7. O157 LAMP primer information (Genbank Accession No.  S83460) 
 
Primer Name Sequence (5′-3′) Position Tm (
°C) 
F3 TTCACACTTATTGGATGGTCTC 943 60.1 
B3 TAACTTGCTCATTCGATAGGC 1,167 60.2 
LoopF TGCAAGGTGATTCCTTAATTCC 1,016 61 
LoopB AGCACCCTATAGCTGAGGAT 1,090 62 
F2 (FIP) ATTCTAACTAGGACCGCAGA 966 60 
F1c (FIP) AACTGGCCTTGTTTCGATGAGT 1,043 64.9 
B2 (BIP) TTAATTCCACGCCAACCAA 1,129 60 
B1c (BIP) TCCACACGATGCCAATGTACTC 1,054 65 




3.2.19 ESR serotyping 
Samples that had tested positive for stx1 and/or stx2 were sent to the National Centre for 
Biodefense and Infectious Diseases at ESR, Upper Hutt, for on-site PCR serotyping. The 
assay in use at ESR is used to identify the wzx gene, which in E. coli encodes the O-
antigen flippase within the O-antigen gene cluster. The wzx gene, along with a variety of 
other serotype-specific genes, show variability between serogroups for use as a 
diagnostic marker of the O-antigen type, although the combined assay in use at ESR can 
only deduce if the genes in the samples match the gene cassettes found in O26, O45, 
O103, O111, O121, or O145 and O157 serotypes only. Samples that were positive for 
O157 in both the LAMP assay and the wzx assay were also subjected to a PCR assay to 
determine their H (flagellar) antigen type through variations of the flagellar antigen 




3.3.1 PCR validation assays and amplification efficiency check 
Each of the individual probe and primer sets were tested individually against DNA 
extracted from the lab cultured STEC strains, and were found to amplify sequences as 
predicted (eae amplified only in O111:K88:H-, stx1 amplified only in O91:H- and stx2 
only in O130:H11, with uidA amplifying in all E. coli samples). A O84:HNM later 
sourced from ESR was found to amplify stx2, contrary to reference information, although 
recurring issues with gel purification prevented sequencing. Similarly, an stx- O157:H- 
reference strain, to be used as a positive control in LAMP testing, was found to be eae+ 
(see Table 3). The amplification efficiencies of the individual validation assays of the 
uidA, eae, stx1, and stx2 probe and primer sets can be viewed in Figures 11 (uidA, eae) 
and 12 (stx1, stx2). The efficiency graphs are essentially a graphical representation of a 
titration of STEC DNA (in this case, the DNA from a phenol-chloroform extracted 
O111:K88:H- culture combined with similarly extracted O130:H11 DNA and O91:H- 
serially diluted in a ten-fold range of 1 ng/reaction – 0.001 ng/reaction and assayed in 
triplicate). The efficiency graphs themselves display plotted Ct values in a linear 
regression for each of the genes at the dilutions of DNA shown. Once the values were 
plotted, the Applied Biosystems Viia7 software was used to analyse the slope of the curve 
to determine the amplification efficiency (how effectively the reaction can double the 
DNA strands per PCR cycle, expressed as a percentage in the ‘Eff96’ category (see 
Figures 11 and 12)). All of the amplifications were noted to have performed efficiently, 
with upwards of 97% efficiency as calculated by the Viia7 software. The software also 
noted a high coefficient of determination (R2) value and low error for each of the standard 
curves generated, which indicates that there was little variation in triplicate repeats of the 
assay. 
3.3.1.1  PCR amplicon size check 
The gel photo of the amplified gel fragments is displayed in Figure 13, alongside an 
Invitrogen TrackIt 1Kb Plus (Cat no 10488-085) molecular ladder. The sequence 
fragments of uidA and eae can be viewed in the wells next to the 100bp ladder fragment, 
which is consistent with the sizes predicted with the Primer Express software. Due to an 
error in dispensing, the stx1 and stx2 fragments were combined in the same gel well, and 
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(a)  (b)  
Figure 11. Amplification efficiencies of each of the individual assays to be merged in the multiplex reaction: (a) uidA probe and primer set; (b) 
eae probe and primer set. Both efficiencies are noted to be in excess of 97%. The efficiencies are an indicator of the ability of the reaction to 
effectively double the target sequence in each thermal cycle. 
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(a)  (b)  
Figure 12. Amplification efficiencies of each of the individual assays to be merged in the multiplex reaction: (a) stx1 probe and primer set; (b) 
stx2 probe and primer set. Both efficiencies are noted to be in excess of 97%. The efficiencies are an indicator of the ability of the reaction to 
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Figure 13. Gel fragments of O84:HNM amplified using the separate assays of the qRT-PCR multiplex (uidA, eae, stx1 and stx2). The predicted 
fragment sizes for uidA, eae, stx1 and stx2 were 94 bp, 102 bp, 107 bp and 130 bp, respectively. All fragments were of the correct size, running 
close to the 100 bp ladder fragment. Due to a pipetting error, the stx1 and stx2 post-PCR amplified fragments were added to the same well, and so 





so the two cannot be distinguished owing to their similar size, but the gel fragment size 
is consistent with the expected size for both fragments.  
3.3.1.2  Multiplex amplification efficiency comparison 
The results garnered in the separate amplification efficiency testings were compared with 
a similar assay incorporating all of the surveyed probes and primer sets in concert within 
one PCR mix. As with the separate assays, the multiplex assay was completed with a five 
point ten-fold dilution range (1 ng/reaction – 0.001 ng/reaction) of appropriately 
extracted O111:K88:H-, O91:H-, and O130:H11 DNA. The AB Biosystems Viia7 
platform appeared to be able to discriminate between the similar wavelengths of the 
fluorescent tags of the stx1 (560 nm) and stx2 (555 nm) probes without incident. The 
amplification efficiencies are recorded in Figure 14 (uidA, eae) and 15 (stx1, stx2). The 
amplification of one reaction, eae, was noted to have had a decrease in its efficiency 
(82.772%; down from an efficiency of 98.748% when conducted as a separate assay). 
However, other tests of this probe and primer set completed after this particular assay 
were found to have high efficiency ratings (see Figure 16(b)). Examining the 
amplification plots of the eae assay in the multiplex PCR revealed a number of outliers 
(see Figure 17), and once these were omitted from statistical analyses, the amplification 
efficiency was noted to increase considerably. 
3.3.2 PCR extraction method yield comparison 
3.3.2.1  Relative DNA yield by cycle threshold values 
The uidA amplification plots of the O111:K88:H- culture as extracted by phenol-
chloroform, PrepMan Ultra kit, Chelex-100 resin, and a simple boiling protocol is shown 
in Figure 18. As the assay functions as a real-time qPCR, the target DNA sequence 
doubles with every thermal cycle, and the fluorescent probes will fluoresce as they attach 
to the sequences being amplified.  The sample with the greatest yield of E. coli DNA 
recoverable after extraction will reach the threshold fluorescence (a default threshold set 
by the Viia7 software) first. The sample processed with phenol-chloroform had the 
highest yield of DNA from the same broth culture relative to the other methods. 
Surprisingly, Chelex-100 was found to have a greater yield than that of PrepMan, with 
the boiling method returning the lowest comparative yield. The concentration of the 
extracted samples as determined by UV spectroscopy are displayed in Appendix 5.
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(a)  (b)  
Figure 14. Amplification efficiencies of each of the assays after testing in one combined reaction: (a) uidA probe and primer set; (b) eae. No 
significant differences in the amplification efficiencies were noted with the exception of eae, which dropped to 82.772% as computed by the 
Viia7 software. The efficiencies are an indicator of the ability of the reaction to effectively double the target sequence in each thermal cycle. 
The high efficiency rating of the uidA assay in the multiplex (comparable to the efficiency seen in the individual uidA reaction in Figure 11) 




Figure 15. Amplification efficiencies of each of the assays after testing in one reaction: (a) stx1 (b) stx2. No significant differences in the 
amplification efficiencies were noted. The high efficiency rating of the stx1 and stx2 assays in the multiplex (comparable to the efficiency seen 
in the individual stx1 and stx2 reaction in Figure 12) indicates they are unaffected by the other reactions taking place in the multiplex. A 





Figure 16. Investigating variation seen in the eae amplification efficiency in multiple testing. Figure 16(a) depicts the eae standard curve 
completed as part of a multiplex reaction as was shown in Figure 14(b). Blue arrows indicate values amongst the triplicate repeats that appear 
to be outliers. A similar assay (shown as Figure 16(b)) of a standard comprised of O84:HNM completed near the time of this assay and with 
the same reaction conditions was noted to have markedly better amplification efficiency by the Viia7 despite a considerable outlier. 
Adjustments to correct the efficiency by eliminating outlying values are depicted in Figure 17. 
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Figure 17. Investigating variation seen in the eae amplification efficiency in multiple testing. Upon examining the corresponding quantities 
(0.1 ng and 0.0001 ng) on the amplification plot of the eae assay (shown in Figure 16(a)), the outlier values were again apparent (red arrows). 
Once these values were removed from statistical analyses, the corrected eae standard curve showed an improved efficiency rating as seen in 
Figure 17(b) (89.483%). 
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Figure 18. Relative DNA yield comparison of a broth culture. A single 6 hour TSB culture of E. coli O111:K88:H11 was extracted by four DNA 
extraction methods; phenol-chloroform phase separation with salt precipitation, PrepMan Ultra (a kit-based protocol), boiling with Chelex-100 resin, or 
by a simple boiling protocol. The extracted DNA samples were then run under identical PCR conditions on a AB Biosystems qCR Viia7 thermocycler, 
amplifying a sequence within the E. coli uidA gene. The method with the highest comparative yield of DNA is that of the phenol-chloroform extraction, 
which has the lowest Ct value. The Chelex-100 resin is noted to have a DNA yield comparable to that of the PrepMan method. 
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3.3.2.2  Gel photos of extracted DNA 
Photos of the gels used to examine the physical state of the extracted DNAs are displayed 
in Figure 19. The phenol-chloroform extracted culture of O91:H- showed the most 
prominent DNA streak when run on an electrophoretic gel, followed by the Chelex-100, 
then boiling, with PrepMan having the least substantive streak. The positions and size of 
the streaks on the gel provide information on the degree of degradation that the DNA 
encountered during the respective extraction procedures, as larger, undamaged DNA 
fragments migrate more slowly across the gel. The DNA processed by the boiling method 
can be seen as a long faint streak running near the bottom of the gel, indicating that the 
DNA itself has fragmented into strands small enough to run ahead of the 2,000 fragment 
seen in the molecular ladder. The phenol-chloroform extracted DNA can be seen to have 
fragments running near the 2,000 bp ladder mark on its respective gel, suggesting some 
fragmentation, but most of the DNA can be seen in a band well above the 12,000 bp 
mark, indicating that most of the recovered DNA is considerably less fragmented. The 
intensity of ethidium bromide staining also suggests the phenol-chloroform bands 
contained the highest concentration of DNA. The Chelex-100 band, while not as intense 
as the phenol-chloroform extracted material, remained in a relatively tight streak near the 
40,000 bp fragment of the DNA ladder. The PrepMan streak is barely visible in the 
circled region of the gel in Figure 19(b), running ahead of the 2,000 bp ladder fragment, 
although not as dispersed as that of the material in the boiling lane. 
3.3.3 PCR-based quantitation 
In order to arrive at a representative weight per genome of stx-bearing E. coli, all of the 
completed chromosomal E. coli FASTA sequences were downloaded from the NCBI 
database and searched for probe sequences using pDRAW software. An example of a 
pDRAW sequence search is demonstrated in Figure 20. The genome sizes of the strains 
(n = 17) that were found to carry one or more of the stx genes (displayed in Appendix 6) 
were then graphed using PRISM software alongside a sample (Figure 21) of non-stx 
carrying E. coli (n = 29; see Appendix 7), and together with the mean GC percentage, the 
mean genome size was used as the basis of calculations to determine a representative 
weight per stx-bearing genome (calculations expressed in Appendix 8). For stx-bearing 
E. coli, this number was determined to be 1.7 x 105 genomes per ng of DNA. With this 




































Figure 19. Gel photos of 6 hour TSB cultures of E. coli O91:H- DNA extracted by either phenol-chloroform, Chelex-100, PrepMan or boiling 
methods. Figure 19(a) depicts the culture processed by boiling and PrepMan extraction methods run against a 1Kb extension ladder 
(InvitrogenTM). The DNA processed by boiling can be seen in a long streak towards the bottom of its lane, while the DNA processed by Chelex 
(arrow) remains near the loading wells, roughly equivalent to the 40,000 Kb ladder marker. The DNA processed by Phenol-Chloroform and 
PrepMan can be seen in Figure 19(b); Phenol has the most easily visible DNA streak running almost the length of the gel, whereas the PrepMan 
streak is barely visible (circled) at about 2,000 Kb as compared to the Invitrogen 1Kb Plus Ladder (Cat. No. 10787-018) used in this gel. The 
negative controls shown in both gels were sterile TSB processed along with the live cultures. 
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Figure 20. Example of a genome sequence search conducted using pDRAW (ACACLONE) software on E. coli FASTA sequences sourced 
from the NCBI E.coli ‘Genome Assembly and Annotation Report’ webpage. Several genomes containing stx genes were used to calculate a 




Figure 21. Box and whiskers plot of the genome sizes of NCBI-sourced FASTA sequences 
with and without stx genes (those displayed in Tables 5 and 6). The means (depicted by a 
cross symbol) of the stx+ (5.609 Mb) and stx- (4.984 Mb) groups were found to be 
significantly different (p = <0.0001). The mean of the stx-bearing E. coli (5.609 Mb) was 
deemed a suitable basis of molecular weight calculations for stx+ E. coli based on the 
apparent absence of outliers and on the low coefficient of variation (2.26%) seen amongst 
the genome sizes of stx-bearing E. coli. 
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Viia7 software to provide an estimate of the number of stx-bearing genomes within a 
given well, whether this be DNA extracted from E. coli broth culture or faecal extracts. 
3.3.4 Stationary-phase O84:HNM growth curve 
The OD600nm readings from the eighteen hour O84:HNM culture experiment can be 
viewed graphically in Figure 22, along with the corresponding CFU (as calculated based 
on the O84:HNM OD600nm curve in Figure 7). The growth curve results showed that 
viable stationary phase E. coli O84:HNM (for use in later spiking experiments) could be 
collected from overnight cultures before the culture entered death phase. The culture that 
was mixed and measured only every three hours appeared to have markedly lower 
OD600nm reads from 6 hours onwards, and shows the effect of agitation on E. coli broth 
culture growth. 
3.3.5 Preliminary Faecal screening 
Five faecal samples (designated α, β, γ, θ, and µ) were sourced from SCL and screened 
for eae, stx1, and stx2 by testing with the multiplex after a 3 hour TSB pre-enrichment to 
select a sample for faecal spiking experimentation that did not contain endogenous stx-
carrying bacteria. Sample α was found to be positive for stx1 and stx2 and the others 
tested negative for all but uidA. Sample β had a large number of E. coli genomes as 
indicated its mean uidA Ct (15. 924) and sample γ had a lesser amount (mean Ct value of 
25.61). Sample β and γ were chosen for subsequent faecal spiking so that comparisons 
in the Ct values between the two could be used to determine if the amount of commensal 
E. coli had any effect on the sensitivity of the test. 
3.3.6 Multiplex sensitivity testing by faecal spiking 
The common limit of detection of the multiplex for the pathogenic genes stx1, stx2, and 
eae within a faecal matrix was deemed to be 2 x 103 CFU (of E. coli O84:HNM) per mL 
of well mixed, unincubated faecal-broth culture (1 part faeces to 9 parts culture medium) 
or 2 x104 CFU per g of faeces for faecal samples β and γ. This was determined by 
examining the fluorescent signals of the corresponding probe markers (Cal Fluor 560 for 
stx1 and TAMRA 555 for stx2) to determine at which spiking concentration the signals 
could no longer be reliably detected (at least two of the three replicate tests at a certain 
spike concentration had to provide a change in fluorescence discernible with AB 
Biosystems 7500 software, as displayed in Figure 23). The limit of detection for the eae 
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Figure 22. Calculated (log-transformed) CFU mL-1 of the 18 hour TSB cultures of O84:HNM E. coli. The OD/CFU measurements 
indicate that the rate of growth amongst O84:HNM E. coli slows after 6 hours when mixed and measured on a 3-hourly basis, reaching 
a mean (non-log transformed) OD of 0.419, as opposed to a mean OD of 0.723 when mixed and measured hourly. The data indicates 
that overnight cultures (c. 18 hours) can be used to acquire stationary-phase E. coli before such cultures enter death phase (which would 
be normally be indicated by a plateau of OD readings). This is done to ensure that the O84:HNM OD curve (depicted in Figure 7) can 













Figure 23. Limit of sensitivity as determined by faecal spike assay. Faecal samples β and γ were spiked with known CFU per g of E. coli 
O84:HNM and extracted with Chelex in conditions matching that intended for the samples in the greater prevalence study (these spiked 
samples were not incubated). The limit of sensitivity was defined as the lowest concentration that all of the pathogenic genes (eae, stx1, and 
stx2) could be detected (at least two of the triplicate tests giving a discernible increase in fluorescence). While eae could be detected in the 
faecal samples inoculated with 2 x 103 CFU of bacteria per g faeces (Figure 23(b)), the lowest common limit was found to be 2 x 104 CFU 
per g of faeces (as depicted in faecal sample β in Figure 23(a); the same result was garnered from sample γ). 
(a); 2 x 104 CFU O84:HNM per g faeces (b); 2 x 103 CFU O84:HNM per g faeces 
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gene was lower than that of stx1 and stx2, with noticeable amplification of eae+ in 
samples spiked with 2 x 103 O84:HNM CFU per g of faeces. After 3 hours of incubation, 
all three pathogenic genes could be detected in both faecal cultures that had been spiked 
with 2 x 102 CFU O84:HNM per g of faeces, indicating the spike bacteria were able to 
be detected at the multiplex’s limit of detection established by the ‘0h’ cultures. 
The similarly designed experiment described in the methods section featuring 
exponential-phase O84:HNM used to spike the β and γ faecal cultures without incubation 
was found to have the same limit of detection (2 x 103 O84:HNM CFU per mL of well 
mixed, unincubated faecal-broth culture or 2 x104 CFU per g of faeces). 
3.3.7 Enumeration of spike replicate 
The overnight TSA plate culture counts of the recreated spikes (see section 3.2.11) plated 
before incubation were counted and the corresponding CFU mL-1 of TSB were 
calculated. The plate counts of the broth inoculated with 2 x 105 CFU equated to 2.2 x 
105 CFU in the whole 10 mL broth. Similarly, the broth inoculated with 2 x 104 CFU 
spike equated to 2.2 x 104 CFU in total in the 10 mL broth. The broth inoculated with 2 
x 103 equated to 2,260 CFU in 10 mL of broth. Although this test could have benefited 
from repeat plating of these cultures, these results are consistent with the O84:HNM 
OD600nm standard curve being reasonably accurate, and that the values expressed in faecal 
spiking experimentation were not influenced by a failure in the O84:HNM OD600nm to 
estimate bacterial CFU concentrations. The plate cultures derived from the same TSB 
cultures that had undergone 3 hours of incubation showed 213 colonies for the culture 
inoculated with 2 x 102 O84:HNM, which equated to 21,300 CFU in 10 mL of broth. The 
post-incubation culture inoculated with 2 x 101 O84:HNM was found to have 3,800 CFU 
in 10 mL of broth. As this experiment was in part completed to determine if O84:HNM 
had a significantly faster growth rate than other E. coli, the equivalent CFU mL-1 (of 
broth) values were plotted against theoretical optimal E. coli growth conditions (see 
Figures 24 and 25). The theoretical optimal conditions themselves were plotted by 
doubling the inoculum concentration for 9 growth cycles of 20 minutes. The values were 
found to be closest to a model assuming that the E. coli did not begin doubling for two 
typical E. coli doubling cycles (40 minutes) once incubation had begun. These results 














TSB incubated with approx 20 CFU ml-1 O84:HNM
Optimal -1 doubling cycle -2 doubling cycles Observed value
Figure 24. Growth characteristics of stationary-phase O84:HNM. Stationary-phase O84:HNM were used to inoculate TSB at the concentration 
shown to elucidate the growth characteristics of this strain in the absence of faeces. The plate count of the culture (yellow dot) retrieved after 
3 hours of incubation at 37°C is consistent with the model proposing that the bacteria spend two growth cycles (40 minutes) in lag phase. 
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Figure 25. Growth characteristics of stationary-phase O84:HNM. Stationary-phase O84:HNM were used to inoculate TSB at the 
concentration shown to elucidate the growth characteristics of this strain in the absence of faeces. The plate count of the culture retrieved 
after 3 hours of incubation at 37°C (yellow dot) is consistent with the model proposing that the bacteria spend two growth cycles (40 















TSB incubated with approx 3 CFU mL-1 O84:HNM
Optimal -1 doubling cycle -2 doubling cycles Observed value
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3.3.8 Plate counts, NanoDrop readings and calculated Ct values comparison 
The plate counts, NanoDrop readings and genome estimates based on Ct readings were 
compared to examine potential discrepancies. The three E. coli O130:H11 cultures 
returned plate counts that equated to 1.88 x 109, 2.03 x 109 and 2.14 x 109. The same 
cultures, when quantitated by averaging triplicate NanoDrop reads of the extracted DNA 
and multiplying this value by the total volume of the extracted DNA, returned values of 
7.77 x 109, 6.92 x 109, and 8.43 x 109 genomes per mL of phenol- chloroform extracted 
broth. When 1 µL of these extracted DNA samples were assayed alongside a (phenol-
chloroform extracted) O130 standard curve, the values of the samples were determined 
to be 6.85 x 109, 5.58 x 109 and 7.59 x 109 genomes per mL of phenol-chloroform 
extracted broth. 
3.3.9 ROX-inclusive master mix validation 
Amongst the four assays within the multiplex, only the uidA assay showed any 
amplification when used with TaqMan Universal Master Mix, and so the endogenous 
dye therein could not be used to correct for the algorithmic correction problem 
encountered with some eae assays. As eae+ samples could be discriminated from 
anomalous readings with use of the ‘multicomponent plot’ function of the Viia7 software 
(as shown in Figures 26 and 27), it was decided to proceed with the use of ToughMix for 
the main faecal assays. 
3.3.10 384-well plate validation assay 
Prior to the 384-well validation, it was found that the Viia7 software required a 
recalibration for the detection of Quasar 670, and it was recommended that 300 nM of 
eae probe per reaction be used for assays involving 384 well plates due to an inability of 
the instrument to detect Quasar at the optimised concentration of 80 or 120 nM. The 
initial assay of a manually loaded 384 well plate was otherwise completed without 
incident; there was no noticeable difference in fluorescence generated or in the sensitivity 
of the multiplex to detect the phenol-chloroform extracted DNA standard compared to 
assays of a 20 µL volume on 96 well plates. An initial test involving the loading of the 
DNA standard and selected processed faecal samples was completed to satisfaction. The 
first 32 Chelex-processed faecal samples collected for the prevalence study were assayed 
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Figure 26. Anomalous Quasar 670 correction problem. An example of a recurring algorithmic correction problem. While an attempt to 
use a qPCR mix with an endogenous dye for signal normalisation was unsuccessful, it was found that truly positive samples could be 
discriminated by examination of the signal change under the ‘Multicomponent plot’ feature of Viia7 and 7500 on a case-by-case basis. 
 




Figure 27. Multicomponent plots. While an attempt to use a qPCR mix with an endogenous dye for signal normalisation of anomalous Quasar 
670 fluorescence signals was unsuccessful, it was found that truly positive samples could be discriminated by examination of the Quaasar 
signal change under the ‘Multicomponent plot’ feature of Viia7 and 7500 on a case-by-case basis. Graph (a) depicts negative samples that 




with the multiplex as part of the 384-well plate validations, the results of which are 
included in the ‘results of main assays’ subsection of the ‘main faecal assays’ section. 
3.3.11 Main faecal assays 
3.3.11.1 Robot-Loaded 384 plate assays 
The initial test of function using 384-well qPCR plates performed as expected; both the 
O84:HNM DNA standard and the select faecal specimens produced clear signals with no 
clear indication that the robot had failed to load the specimens. The subsequent loading 
of the processed faecal samples into the 384-well plate proceeded without incident, 
however the amplification failed, with the wells appearing under filled. A cursory test of 
robotic dispensation of a viscous solution with a water and glycerol solution indicated 
the robot loader was dispensing appropriately. A second attempt of the robot loading was 
met with mixed results; despite adapting the loading protocol to account for possible 
dispensing inefficiencies, much of the right hand side of the 384-well plate appeared 
underfilled, and many of the samples that appeared filled showed no amplification of the 
tentative faecal sample amplification control uidA. It was decided to assay the remaining 
faecal samples (and those failed samples from the reattempted 384-well assay) on 96-
well plates with manual loading and a reduced volume. 
3.3.11.2 Validation of reduced volume 96-well assay 
The validation of the multiplex with conditions of reduced volume performed as 
expected; the assay could detect 100 ng of O84:HNM without an appreciable loss of 
florescence when the reagent volumes (except the sample) were reduced by factor of two 
from 20 µL per well to 10 µL per well. 
3.3.11.3 Remainder of main assay testing 
The remainder of processed faecal samples were processed on 96-well well assay plates 
on the AB Biosystems 7500 thermocycler without need for assay redesign, although 
some samples did not display any amplification. 
3.3.11.4 Results of main assays 
Collectively, of the 522 processed diarrhoeic stool samples that were tested across the 
assay types described above, 8 were recorded as testing positive for either stx1 or stx2, 
equating to a prevalence of 1.53% (0.66 – 2.99%; 95% CI). The patient details of the stx 
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positive samples are recorded in Table 8; this table incorporates serotype data from the 
ESR testing section and samples that were in the H. pylori group. Amongst the 50 
samples that had been set aside for H. pylori testing, 3 tested positive for stx1 or stx2, 
equating to a prevalence of 6% (1.25 – 16.54%; 95% CI) in this group (these samples 
tested negative for H. pylori). A Fisher’s exact test could not determine a statistically 
significant difference in the STEC prevalences between these two groups (p = 0.063; 
95% CI). No STEC were found within the 26 faecal samples set aside for faecal 
calprotectin testing. Overall, 26 samples tested positive for eae. Amongst the main pool 
of samples, 23 (4.41%) samples tested positive for eae (2.96 – 6.53%; 95% CI), two of 
which were later found to be serotype O157:H- (for a breakdown of these samples and 
related information, refer to Table 9). Two specimens amongst the faecal calprotectin 
samples (n = 26) were found to be positive for eae, but the prevalence of eae+ only E. 
coli in this group was not found to be significantly different from that of the main group 
(p = 0.298827; 95% CI). 
3.3.12 PVPP column testing 
3.3.12.1 Initial test of PVPP processing of faecal samples and BSA assay 
The initial test of PVPP columns and BSA, displayed as a comparison of the triplicate Ct 
values of the specimens with and without the post-extraction treatments, are displayed in 
Figure 28. The four Chelex-processed samples chosen were #157, a specimen that had 
displayed an acceptable uidA amplification on the reattempted 384-well assay, and 
samples #131, #134, and #139, which showed no amplification on the 384-well assay 
(although it remained unclear at this time whether the lack of uidA amplification in these 
wells was as a result of PCR inhibition or the robotic platform not having dispensed the 
processed faecal samples appropriately). The Ct values of #139 were the most consistent 
with the expected pattern of inhibition; the assay failed to amplify but was able to with 
PVPP processing. The variability of the triplicates of sample #131 appeared to decrease 
markedly with PVPP processing. Sample #134 did amplify in this testing without PVPP, 
suggesting the lack of uidA amplification seen in this well on the 384-well assay prior 
was more likely as a result of mechanical error by the platform. The Cts of sample #157 
and #134 actually increased with PVPP processing. The addition of BSA to qPCR mixes 
assaying the PVPP-processed samples resulted in no significant change in Ct values. The 
test of the 96-well Silicon-A-HRC purification plate with sample #139 indicated that the 
plate could not improve Cts as demonstrated by tests with the individual microcentrifuge 
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TABLE 8: Patient status, serotype and stx types for stx+ faecal samples detected 
 
Sample number designate Age In/Out patient Serotype (ESR) eae Status Stx1 status Stx2 status 
22 ≥12 Inpatient ?   positive 
25 ≥12 Outpatient ?   positive 
36 ≥12 Outpatient ?  positive positive 
271 ≥12 Outpatient ?  positive positive 
284 ≥12 Outpatient O157+, O103+ positive positive positive 
370 ≥12 Outpatient ?   positive 
511 ≥12 Inpatient ?   positive 
547 ≥12 Outpatient O157+, O103? positive weakly positive weakly positive 
       
Stx+ samples from the H. pylori pool 
Sample number designate Age In/Out patient Serotype eae Status Stx1 status Stx2 status 
92 ≥12 Outpatient ?  positive positive 
456 ≥12 Outpatient ? positive positive positive 
461 ≥12 Outpatient ?  positive positive 
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TABLE 9. Patient status, stx types, and other test details for eae+ faecal samples detected 
(continued on next page) 
Sample number designate Age In/Out patient Stx1 status Stx2 status Details 
12 ≥12 Outpatient    
16 ≥12 Inpatient    
17 ≥12 Outpatient    
86 <12 Outpatient    
88 <12 Outpatient   NSF colony sent to ESR, no Shiga toxin detected 
89 ≥12 Outpatient    
117 ≥12 Inpatient    
160 ≥12 Inpatient    
266 <12 Outpatient    
278 ≥12 Outpatient   NSF colony sent to ESR, no Shiga toxin detected 
284 ≥12 Outpatient positive positive  
287 <12 Outpatient    
288 ≥12 Outpatient    
291 ≥12 Outpatient   NSF colony sent to ESR, no Shiga toxin detected 
324 ≥12 Outpatient    
344 <12 Outpatient    
378 <12 Outpatient   Faecal calprotectin sample; quantitative test negative 
380 <12 Inpatient   Sample tested positive for Campylobacter, Salmonella 
418 ≥12 Inpatient   Faecal calprotectin sample; quantitative test negative 
440 ≥12 Outpatient    
456 ≥12 Outpatient positive positive H. pylori sample (antigen negative) 
489 <12 Outpatient    
506 ≥12 Outpatient    
524 ≥12 Inpatient    
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TABLE 9 (continued) 
 
Sample number designate Age In/Out patient Stx1 status Stx2 status Details 
547 ≥12 Outpatient weakly positive weakly positive  
600 ≥12 Outpatient    





Figure 28. Test of function with PVPP columns. Four Chelex extracted faecal samples of 
dubious assay status were processed with PVPP columns and part of these processed samples 
were also amplified in a qPCR mix incorporating BSA to determine if PVPP or BSA made 
any discernible improvement in Ct or permitted amplification to occur. The red lines indicate 
the statistical significance between groups of Ct values by concentration, as determined by 
ANOVA analysis (GraphPad Prism software); * denotes p < 0.05, ** denotes p < 0.05, and 
*** denotes p < 0.01. The PVPP processing did appear to permit sample #139 to amplify and 
appeared to reduce the variability in Ct values seen in #131, although it did induce significant 
increases in the Ct values of #134 and #157. The only significant effect on Ct values induced 
by adding BSA to the qPCR mix appears to be as a result of a considerable (disregarded) 
outlier in sample #139. As the PVPP columns could demonstrably remove putatively 
inhibitory substances from samples with poor amplification patterns, it was decided to process 





PVPP columns. Based on these results, it was decided that it would be worthwhile to 
process the samples that had shown poor amplification of uidA in the main assays with 
the individual PVPP columns, to see if any improvement in Ct values could be made. 
3.3.12.2 Main PVPP processing and retesting of questionable samples 
Of the 95 samples from the main assays retested after PVPP column processing, only 
five appeared to have any noticeable decrease in Ct values. Most samples showed little 
or no improvement with PVPP processing, with 26 showing no amplification before or 
after PVPP processing. Four samples that had high but very close duplicate Ct values in 
the main assays showed complete degradation of their signals following PVPP 
processing. 
3.3.12.3 Internal amplification testing of selected PVPP-processed samples 
The Ct values of the internal amplification control are displayed in Figure 29. ANOVA 
analysis showed no significant difference between Ct values of the internal amplification 
control in wells that contained any of the processed faecal samples and that of the 
included negative (no added DNA) control. Similarly, no significant difference in the 
internal amplification control Ct values could be determined when comparing each faecal 
specimen that had been processed by PVPP with the equivalent specimen that had not 
undergone PVPP processing. 
3.3.13 LAMP based detection of O157 serotypes 
The initial test of the LAMP primers and PCR mix on the Viia7 thermocycler produced 
no amplification in any of the stx+ samples or controls, despite replication of the cycling 
parameters described in the PCR mix insert. When the assays were completed on the 
Genie platform, faecal samples #284 and #547 showed SYBR green fluorescence 
comparable to that of a Chelex-extracted O157+ control (the #547 and positive control 
are depicted in Figure 30; Figures 30 and 31 are provided as photographs of the Genie II 
display due to a malfunction of the platform to transfer data via a USB port). Melt curves 
provided by the software (occurring during the annealing stage of the programmed 
parameters) showed the products in the faecal samples were in consensus with the 
provided control (see Figure 31).
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Figure 29. Internal amplification check of resolutely negative extracted samples. An internal amplification probe (pChook IAC) was added to 
a qPCR mix and used to determine whether a subsample of Chelex-extracted specimens that showed no amplification of target sequences were 
under the influence of PCR inhibitors. The assay also incorporated a test of PVPP processing; each sample’s internal amplification Ct values 
would be compared against the same specimen that had undergone PVPP processing as well as against a negative control (to which no DNA 
had been added, shown in red on this graph). None of the Ct values showed a significant difference from the ‘No DNA’ control when analysed 
by ANOVA analysis (95% CI), signifying that samples were not under the influence of PCR inhibitors. 
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Figure 30. Genie II display featuring O157+ sample amplification. Faecal sample #284 (green line) is shown amplifying alongside a 
positive control (Chelex-100 culture of O157+ E. coli). A melting curve analysis of these samples can be viewed in Figure 31. 
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Figure 31. Genie II display featuring O157+ melt curve analysis. Faecal sample #284 (green line) can be seen here with a melting signature 
equivalent to that of an E. coli O157+ control. An accompanying table display listed the sample and control to have peak annealing 
temperatures of 84.65°C and 84.64°C, respectively. A very similar temperature (84.77°C) was recorded for the other faecal sample designated 




3.3.14 ESR serotyping 
The serotyping results from ESR indicated that faecal specimens #284 and #547 were 
positive for O157, in concordance with the LAMP-based serotyping carried out by the 
researcher. #284 also tested positive for O130. A trace of O130 was also detected in #547, 
however the low intensity of the fluorescent signal meant this result was not conclusive. 
Both #284 and #547 tested negative for the common O157 flagellar antigen H7. None of 
the stx+ samples other than #284 or #547 could be serotyped, signifying that none of the 




3.4.1 PCR validation assays and amplification efficiency checks 
The amplification efficiencies were found to be over 97% when tested separately. Ideally, 
qPCR efficiencies should be 90-105% (132), although 100% efficiency as computed 
from a five order-of-magnitude dilution series is recommended for the quantification of 
E. coli from environmental samples (93). The primer sequences used in this project were 
adapted from sequences developed for multiplex use by Nielsen et al, and have been 
previously tested against GenBank sequences to ensure specificity (46). A cursory test 
of specificity was carried out through individual eaeA, stx1, stx2 amplification reactions 
with strains known to be lacking each of these genes. Multiplexing PCR reactions can 
elicit the formation of dimerised or secondary structures that can selectively impede 
amplification of one or more targets (111, 133). The formation of such structures cannot 
be reliably predicted by primer design software, and so empirical testing is usually 
necessary to determine if any one primer pair interferes with other amplifications in the 
multiplex (134). The forward and reverse primer sequences for uidA were redesigned for 
this project to have a closer annealing temperature to that of the other primers in the 
multiplex (as an additional measure to improve amplification consistency (133)). The 
multiplex efficiency test was necessary to ensure that the new primers did not impinge 
upon the efficiency of the other reactions. It was found that the eae reaction efficiency 
was adversely affected by multiplexing. However, on closer examination, it was found 
that the poor reaction efficiency was as a result of variation between triplicate wells 
probably due to technical error and this did not occur in subsequent experiments. The gel 
electrophoresis of the separate assays showed that fragments of the correct size were 
being amplified, and although the stx2 fragment could not be differentiated from stx1 on 
the gel, subsequent RT-PCR assays showed amplification of the target in expected E. coli 
strains. In review, the fragment gel electrophoresis should have been repeated to clearly 
distinguish stx1 and stx2 fragments and mitigate the dark banding caused by the loading 
dye. As the primers had undergone specificity testing in two papers (46, 82), and as the 
gel was not inconsistent with the expected fragment sizes, a repeat was postponed at the 
time in favour of other experiments owing to time constraints. Several attempts to 
sequence fragments from this and a similar gel with the use of a Wizard® SV Gel and 
PCR Clean-Up System failed. 
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3.4.2 PCR extraction method yield comparison 
The comparison of the four extraction methods by RT-PCR and gel electrophoresis 
revealed that the phenol-chloroform extraction gave the greatest yield of DNA from a 
pure broth culture compared to the other extraction methods. Chelex-100 had the next 
highest yield, performing better than PrepMan Ultra or the simple boiling protocol. The 
phenol-chloroform method is regarded as a classic DNA extraction gold standard and is 
often used as a basis of comparison for the efficacy of DNA extraction methods (128, 
130, 135, 136). Surprisingly, Chelex-100 permitted the amplification of a better yield of 
DNA than the kit-based PrepMan method, and appeared to result in less DNA 
fragmentation upon DNA analysis. Little information is available on the mode of action 
of the PrepMan Ultra reagent, but the extraction method has been used in several studies 
involving the extraction of STEC from pure broth culture, bovine faeces and beef samples 
(82, 137, 138). PrepMan is not recognised to be the most ideal extraction method, with 
one study finding a modified TE heat lysis extraction more effective (138), and another 
correlating the use of larger volumes of the reagent with PCR inhibition (139). Chelex-
100 resin is composed of styrene divinylbenzene copolymers containing paired 
iminodiacetate ions which chelate polyvalent metal ions in solution (140). Chelex-100 is 
effective over all biological pHs (140), and has been demonstrated to have a extraction 
efficacy comparable to that of phenol-chloroform in a variety of human tissues (128, 130, 
141, 142). Due to concerns of the influence of proteins and other particles left over from 
Chelex-based extraction on spectroscopic readings, it was decided to measure the 
effective yield of amplifiable DNA by PCR rather than direct DNA spectroscopy (131). 
Chelex is speculated to prevent DNA degradation by chelating metal ions that act as 
catalysts at high temperatures in solutions of low ionic strength (141, 143), while also 
binding porphyrin inhibitors from blood (126). The boiling method offers nothing in 
advance of the PrepMan or Chelex methods, relying on temperature and centrifugation 
of the sample to selectively denature and remove PCR inhibitors.  
Cost, sensitivity and practicality of the extraction methods were considered before 
choosing an ideal method for the project. The phenol-chloroform method, whilst an 
industry benchmark, was time-consuming to perform on multiple samples, and involved 
the use of toxic organic solvents not suited to extensive or high throughput testing. The 
phenol-chloroform protocol also had more washing and transfer steps that could increase 
the risk of introducing contaminants to the samples (126). The Chelex and PrepMan 
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methods could be typically completed within one hour without the use of a fume hood, 
and had demonstrably less DNA fragmentation than the simple boiling extraction (visible 
as a low molecular sized streak on the gel in Figure 19). The PrepMan Ultra kit was 
valued at NZ $173.00 for 200 preparations (87¢ per test), while the Chelex-100 resin was 
valued at NZ $456 for 5500 preparations (8¢ per test). It was decided to proceed with use 
of Chelex on the basis of cost and the comparative DNA yield as a means to maximise 
sensitivity. In retrospect, a comparative test of Chelex-100 and PrepMan efficacy in 
extracting STEC from pre-spiked faecal samples would have been an appropriate 
accompanying test. An analysis of the four extraction methods would also benefit from 
an analysis of Ct values versus concentration to control for inconsistencies in 
amplification efficiency wrought by any particles left over from each extraction method. 
Ideally, more extensive testing, perhaps comparing more specialised kit-based tests such 
QIAamp DNA Stool Mini Kit or ZR Fecal DNA MiniPrep to Chelex-100, could be 
undertaken to give a more thorough assessment of comparative DNA yield and cost 
effectiveness (136).  
3.4.3 PCR-based quantitation 
One of the early objectives of the project was to investigate the potential to derive 
quantitative information on STEC in active infections. The survey of genome sizes of 
stx+ E. coli provided a representative average genome size (5.609 Mb) from which the 
number of STEC genomes in a sample (by weight of DNA, 174,000 genomes per ng) 
could be estimated. Due to differences in chromosomal sizes between STEC and non-
pathogenic E.coli alluded to within the literature (16, 144, 145), size sampling was used 
to determine a representative average of STEC genome size. It was reasoned that RT-
PCR could be used to arrive at estimates of the number of STEC per gram of faeces in a 
manner similar to other PCR-based studies (82, 93, 146-149), but both the 
implementation and relevance of quantitation of STEC has proven to be problematic.  
While the Viia7 platform could be configured to arrive at estimates of genomes per 
reaction, discrepancies emerged between the values obtained by plate counts, the values 
determined by UV spectroscopy of bacterial DNA and the genomes/mL as calculated 
from Ct values in a subsequent qPCR reaction. These discrepancies were not unexpected, 
as differences between plate counts and PCR-based techniques can arise through a 
confluence of the presence of viable but non-culture cells, the aggregation of cells on 
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plate media and the influence of growth dynamics on genomes per cell (150, 151). These 
discrepancies could be corrected by deducing the conversion factor for genomes detected 
by PCR to the number of cells present (150), but further testing was not pursued in favour 
of other experiments. In retrospect, Chelex-processed faecal samples pre-spiked with 
known concentrations of STEC on a log10 scale, like that performed by Ibekwe et al (93), 
would have been a more appropriate standard curve for faecal STEC enumeration. The 
method also needed further testing with a range of faecal samples to determine what 
proportion of total faecal DNA was lost during Chelex-based extraction before reliable 
genomes/gram faeces estimates could be placed. Attempts to use the phenol-chloroform 
extracted pure culture standard curve of O84:HNM to quantify O84:HNM within spiked 
Chelex-extracted faecal samples yielded estimates inconsistent with the known spike 
concentration, even when accounting for the different sample extraction volumes 
generated by the two extraction methods. During the collection phase of this project, a 
rough estimate of volume was noted for faecal samples that were either too viscous to be 
pipetted accurately or less than 1 mL. In review, these estimates would have led to further 
error in genomes/gram estimates had quantitative information been sought. A more 
appropriate technique would have been to record the net weight of faeces added to the 
broth universals and to use these values as a basis of subsequent calculations. Growth 
dynamics of the resident STEC were also considered to be a possible confounder; 
although the 3 hour TSB pre-enrichment would limit the amount of growth variance 
between strains, some system of correcting differential growth would have to be 
implemented. It is difficult to estimate the effects of these enhancements in the method 
without further testing, and a lack of standardised protocols for the quantification of 
pathogens in faeces by PCR has not helped (117). 
In addition to technical impediments, the nature of STEC infection ultimately limits the 
relevance of faecal genome estimates in diagnostic practice. The secretion of free Shiga 
toxin within the mammalian intestine is thought to be mediated primarily by the rare but 
spontaneous induction of the resident Shiga prophage, such that a subpopulation of the 
infecting STEC strain lyses and releases toxin and lysogenic phage particles (26). The 
basal level of this form of expression is recognised to vary from strain to strain (106, 152, 
153), and as there are over 150 serotypes of non-O157 STEC associated with human 
disease (3, 8), it can be seen that the number of resident STEC may not be a reliable 
indicator of disease severity (59). On the basis of these findings, it was deemed that 
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quantitative information on STEC infection was not a priority to the project, and 
subsequent experiments were directed towards maximising sensitivity and adapting the 
assays to high throughput specifications.  
3.4.4 Stationary-phase cultures, faecal spiking 
The stationary-phase O84:HNM experiments were conducted to ensure that viable 
O84:HNM could be obtained from static overnight TSB cultures so as to provide a 
growth model representative of naturally STEC-infected faeces for subsequent faecal 
spiking experiments. The use of chilled, stationary O84:HNM stems from an evaluation 
of short pre-enrichments by Arthur et al (118), which emphasised the importance of 
matching STEC growth characteristics – most notably replicating the lag phase – that 
would be found in naturally contaminated samples. The physiological state of the target 
cells also has an effect on PCR efficiency (134). The stationary phase culture 
demonstrated that 600 nm OD reads using the O84:HNM OD curve could be used to 
dilute overnight cultures for spiking experiments without the strain’s death phase 
affecting the accuracy of the curve. 
The faecal screening assays ensured candidate faecal specimens for spiking did not have 
endogenous STEC and acted as a cursory test of the culture conditions to be used for the 
main assays. 
The faecal spiking experiment was conducted to determine the common limit of detection 
(LOD) of the STEC pathogenic genes in spiked faecal samples, as performed in similar 
studies (85, 116). As there is some conjecture regarding the effect of endogenous faecal 
E. coli on the sensitivity of PCR assays (85, 95, 102, 154), faecal samples β and γ, with 
a large difference in their endogenous E. coli populations, were chosen. The three 
pathogenic genes could be detected at 2 x104 CFU per g faeces in TSB cultures of 
samples β and γ before incubation. This limit matches the capabilities of similar TaqMan 
PCR assays without enrichment (97, 100, 101). The LOD was consistent across the two 
faecal samples and with their exponential-phase equivalents, indicating that the 
sensitivity of the pathogenic gene assays were not affected by the levels of the 
endogenous E. coli nor the growth phase of O84:HNM. The pathogenic targets could be 
detected in samples inoculated with 2 x 102 CFU per g after 3 hours of incubation. The 
ability of the stationary, cold-stressed STEC to multiply that rapidly in faecal specimens 
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in 3 hours raised concerns that the OD curve was inaccurate and the spikes had not been 
diluted properly. The following experiment, using plate cultures to confirm dilutions of 
stationary O84:HNM based off the O84:HNM OD curve, verified that the dilutions were 
accurate. The plate counts of the same culture after a 3 hour incubation indicated that 
stationary-phase O84:HNM spent only approximately two E.coli generation cycles in lag 
phase (108). In reviewing literature, the replication cycle time for STEC at 37°C was 
found to be slightly shorter (18.1 minutes) than anticipated (approximately 20 minutes) 
(108). It is therefore feasible that the STEC strain used could have multiplied to the level 
of detection in the 3 hour period, but concerns persist that the laboratory-reared 
O84:HNM may overestimate the performance of the incubation to resuscitate STEC 
sourced from faecal samples (118, 155). 
Hidaka et al makes reference to competitive primer testing for STEC genes (92). The 
amplification of a gene target with a large concentration difference to others in the assay 
(as with uidA in some samples) may influence the amplification of the targets with lower 
concentrations. Future sensitivity testing would benefit from testing samples with 
disproportionate concentrations to determine if this effect is negligible with the primers 
used.  
3.4.5 ROX-inclusive master mix validation 
The attempt to substitute the no-ROX ToughMix with a readily accessible ROX-
inclusive qPCR mix was unsuccessful. A no-ROX ToughMix was recommended by the 
distributor (DNature; personal communication) as some molecular “cross-talk” had been 
experienced between ROX (λ = 610) and TAMRA (λ = 555) by other clients. Normally 
the endogenous ROX dye functions as a baseline fluorescence for the normalisation of 
other fluorescent signals and is incorporated to account for minor variations in plate 
characteristics, volumes, or the quality of the optical system (88). As the algorithmic 
correction problem could be circumvented, and as sensitivity of the assay was more 
important than refining the reproducibility, it was decided to proceed with the ToughMix 
qPCR mix. Testing of ROX-inclusive ToughMix was not an option due to time and 
budgetary constraints, but exists as an option that could be explored for future studies. 
Alternatively, probes that fluoresce at infrared wavelengths can be used to minimise the 
influence of background fluorescence (86), but the platforms available for use with this 
project were incapable of measuring fluorescence at this part of the spectrum.  
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3.4.6 384-well plate assays 
Adapting the multiplex assay to 384-well plates did result in a decrease in fluorescence 
amongst test specimens, but the assay experienced no significant reduction in sensitivity. 
The first 384-well plate to be loaded and assayed appeared to have been underfilled. It 
remains unclear to the researcher what happened to this fluid, as the interval between 
dispensation by the robot and the covering of the plate with an optical seal (which would 
later form a hermetic seal on the heating block within the thermocycler) was not long 
enough to account for evaporation. No significant amount of ToughMix remained within 
the source microcentrifuge tubes on the platform. The only plausible explanation at the 
time was that the viscosity of the qPCR mix had caused the pipette tips to dispense 
erratically, and perhaps discarded the excess fluid into the run-off container on the 
platform. The subsequent cursory test of robot dispensation suggested the robot loader 
was capable of dispensing and mixing a viscous solution appropriately. 
As for the loading of the reattempted plate, the underfilled wells on the right half of the 
plate occurred due to a build-up of airspaces in the source microcentrifuge tubes of the 
qPCR mix. As the wells on the right side were the last to be filled by the robot loader 
programme, a combination of qPCR mix viscosity and recurring airbubbles within the 
dispensing tips meant that tips would frequently dispense nothing to these wells. This 
second loading took place under direct observation. Increasing the number of dispensing 
tip changes (during the qPCR mix distribution step in the programme) did not prevent 
erratic dispensation. As there was no clear solution to ensuring that ToughMix-based 
solutions would be dispensed consistently by the loader, and due to budgetary constraints 
prohibiting any more extensive testing with ToughMix on 384-well plates, it was decided 
to revert to the use of 96-well plates, albeit with reduced volumes of reagents if feasible. 
3.4.7 Results of main assays 
The prevalence of stx and eae within samples sourced from Dunedin Hospital were found 
to be 1.53% and 4.41% (95% CI) respectively. The stx genes denote the presence of a 
subpopulation of Shiga toxin E. coli, while eae is a marker of the LEE mechanism, a 
characteristic feature of EPEC. As with other surveys of diarrheic stools (156-159), the 
presence of STEC or EPEC is indicative rather than conclusive of the aetiology of 
diarrhoea in each case,  as the presence of both EPEC and STEC in asymptomatic 
subjects are a common occurrence (157, 160-162), the level of expression of the toxin 
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can be strain dependent (106, 152, 153), and diarrhoea may have non-infectious 
aetiologies. Nonetheless, the lack of other co-infecting pathogens in surveyed STEC 
samples (160, 162), and the strong association of the stx and eae genes with diarrhoea 
(22, 33, 50, 57), is suggestive that STEC and EPEC are the causative organism of 
diarrhoea in these patients. In reviewing the SCL microbiology test results for patients 
positive for stx genes, it was found that no aetiology had been reported. No other cause 
of diarrhoea was resolved for all but one of the patients that tested positive for eae 
(EPEC). There is currently no methodology in place at the Dunedin branch of SCL to 
detect EPEC. As the STEC prevalences determined are those for diarrhoeal stool 
samples, and as diagnostic laboratories that report to surveillance bodies do not test for 
all STEC (7), the STEC or EPEC prevalences in this project cannot be compared directly 
with population incidences as typically detailed in surveillance reports (13, 163). 
Moreover, it is inappropriate to compare project prevalences to regional STEC infection 
estimates as the Dunedin branch of SCL services regions outside that of Otago, including 
the Marlborough, Taupo, and Blenheim regions. Previous international studies reported 
the prevalence of STEC ranged from 1.2% - 3.49% amongst adults and children with 
diarrhoea (156, 159, 164), with higher rates usually seen in studies sampling children 
exclusively (158, 164, 165). As can be seen in Table 8 in the Results section, all of the 
STEC positive samples were sourced from patients ≥12 years of age. Although the 
overall STEC prevalence is comparable to other countries, the age group distribution of 
the stx positive samples is in contrast to international trends (43, 48, 156, 158, 159, 164, 
165).  
As many studies report the highest frequencies of STEC infection in children (2, 7, 36, 
43, 48), it was expected that most or all of the positive samples would be from patients 
≤12 years of age. The lack of STEC infection reported among children is unusual, but 
the milder course of non-O157 infection (21, 32, 36, 166), and the tendency to not seek 
medical attention for less severe infections may contribute to underdiagnosis in this age 
group (167). All of the non-O157 STEC samples were positive for stx2 and none were 
found to carry the stx1 toxin variant alone, contrary to the frequencies of these variants 
seen in European studies (21, 32, 168). stx1-only STEC infections are associated with 
more mild symptoms and uncomplicated diarrhoea and so may also be subject to 
underreporting (2, 33). It is also possible that the lack of stx1-only STEC samples reflects 
country-to-country strain differences, as stx1-only STEC strains have been isolated from 
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Australian HC and HUS sufferers (169), despite previous studies indicating Stx1 is much 
less toxic than Stx2 (5, 15).  
An important factor to consider regarding these results is the seasonality of STEC 
infection. The highest rates of STEC isolation are typically encountered in the warm 
seasons of most countries (7, 10, 165, 170, 171). For Australia, this is roughly months 
December – February (10, 163, 169), whereas New Zealand generally experiences the 
highest rates in the months January – April (13, 72). The survey period for this project 
was 4th of July – 8th August, effectively the New Zealand winter, and a low period for the 
STEC infections reported to ESR in that year, as displayed in Figure 32. As such, the 
STEC prevalence reported for this study likely represents a baseline infection rate. The 
marked seasonality seen in New Zealand is attributed by some authors, as in other 
countries (163, 165), to increased consumption of undercooked meats during summer 
months (172). A recent New Zealand based study by Jaros et al, however, found no 
association of STEC infection with the consumption of contaminated foodstuffs, instead 
finding contact with pets, farm animals, manure and environmental water sources as 
important risk factors (72). Contact with animal manure is a leading risk factor for STEC 
infection in other countries (173, 174), and along with animal contact, is a commonly 
identified activity amongst surveyed STEC patients in New Zealand (13). Several studies 
allude to improved survival of STEC in cowpats, effluent, and on environmental surfaces 
in warmer ambient temperatures (63, 93, 175, 176), while others reference the increased 
shedding of STEC by cattle during summer months (35, 177, 178). It is likely that STEC 
infection seasonality is as a result of these factors acting in conjunction with increased 
outdoor activity during the New Zealand summer (72). It may be worthwhile testing the 
stx2, eae- STEC samples with O104:H4 serotype-specific primers in case this prolific 
European strain is resident in New Zealand (55, 179). 
An intriguing finding has been the discovery of a 6% prevalence of STEC infection 
amongst diarrhoeic samples undergoing testing for H. pylori. Faecal samples suspected 
of H. pylori infection by physicians are sent to SCL for enzyme immunoassay antigen 
testing (Premier Platinum HpSA© Plus), separate to the main panel of faecal tests. The 
samples set aside for H. pylori testing at SCL were prospectively tested for the presence 
of STEC and EPEC. H. pylori infection usually presents with symptoms of dyspepsia 
and reflux in association with gastric and duodenal ulcers (180, 181). A recent review of 
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Figure 32. STEC infections by month, January 2009 – December 2014, as published by ESR. STEC infections as reported to ESR generally 
have the highest incidence in the New Zealand summer and autumn months (February – May). The sampling period (4th July – 7th August 
2014) for the project is shown between the red lines. It should be noted that although the reported data does establish New Zealand seasonality, 
the prevalences as reported by ESR cannot be directly compared to project findings as many laboratories do not employ molecular discovery 
of all STEC serogroups. 
Data sourced from ESR Annual surveillance report 2014, available at: https://surv.esr.cri.nz/surveillance/annual_surveillance.php  
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New Zealand primary care consultants found that many patients also present with 
symptoms of abdominal pain (182), and so it was theorised that an overlap in symptoms 
with that of STEC and EPEC infection may lead to improper testing. Chronic H. pylori 
infection is associated with gastric achlorydria (183), and as this may improve survival 
of ingested STEC or EPEC transiting the stomach (105), the H. pylori samples were 
examined to determine if there was a significant rate of co-infection. A Fischer’s Exact 
probability test did not indicate that there were more STEC among H. pylori samples 
than encountered in other diarrhoeic stools (p = 0.063; 95% CI), but as there were only 
50 surveyed H. pylori samples, the result is indicative that more extensive testing may 
establish significance. None of the samples that tested positive for STEC or EPEC were 
found positive by faecal H. pylori antigen testing, and a lack of published research has 
led the researcher to disregard co-infection with H. pylori having a significant role in 
STEC or EPEC infection. Put together, the H. pylori findings indicate that a small 
proportion of samples sent for H. pylori testing may be misidentified STEC infections. 
As stated, the prevalence for eae was found to be 4.41% of the main pool of diarrheic 
stools surveyed. As EPEC is billed as a primary cause of infantile diarrhoea in developing 
countries (43, 161), it was expected that most of the samples positive for EPEC would 
be derived from patients ≤12 years of age. It was found that 15 of the 23 (65.2%) samples 
that tested positive for eae only were from patients ≥12 years of age, and that most of all 
eae patients were outpatients. It is difficult to infer, at least without more detailed patient 
information, exactly what has led to the infection demographics seen. While some studies 
do point to EPEC being associated with travel (184), EPEC is not implicated as a cause 
of traveller’s diarrhea to the same extent as enterotoxigenic E. coli (ETEC) in countries 
with high endemic rates of EPEC (43). As patient personal information remains 
confidential, the precise role of tourism or agricultural practice on EPEC demographics 
seen here remains somewhat notional. As the regions surveyed by the Dunedin branch of 
SCL are largely rural, and New Zealand cattle and sheep are significant reservoirs of 
STEC and EPEC (185), the most likely source of infection is direct contact or exposure 
to foods or water sources contaminated by bovine or ovine faeces (72). The variable rates 
of asymptomatic carriage of EPEC between countries (157, 161, 186-188), and the ability 
of EPEC to spread through person-to-person transmission (189), suggest that humans 
may also act as transitory reservoirs of endemic infection. Investigating EPEC 
epidemiology further would likely require in-depth region- or occupation-stratified 
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questionnaires and would benefit from an assessment of the prevalence of EPEC in 
healthy human stools. 
As EPEC is a focus of childhood diarrhoea research, few studies exist that document the 
prevalence of EPEC in diarrhoeal stools sourced from both children and adults. Perhaps 
the most comparable prevalence data is that of an Australian study conducted by Staples 
et al in 2013, which returned an EPEC prevalence of 6.8% from mostly diarrhoeal stools 
collected throughout Queensland from 2008-2011 (190). The highest prevalence of 
EPEC in this study was recorded amongst children <5 years of age (17.2%). A 2001 
Finnish study by Keskimaki et al reported an EPEC prevalence of 2.3% amongst 
diarrheic patients (54). A study in Beijing by Qu et al reported a prevalence of 0.9%, a 
prevalence less than that of other enteric pathogens such as Salmonella and Shigella 
(171). Another study in Germany of diarrhoeic and non-diarrhoeic stools reported a 
prevalence of 8.9%, greatly exceeding that of other enteric pathogens (184). The 
prevalence of EPEC in children varies considerably from country to country (2.8 – 27%) 
with differing rates of asymptomatic carriage (157, 186-188, 191, 192). The highest rates 
of EPEC infection occur in the warm seasons of countries (171, 187), although 
seasonality appears to be less marked for EPEC in younger children (193). 
In reviewing the SCL microbiology test results for patients positive for EPEC, it was 
found that very few samples had an aetiology for the diarrhoea determined. Although 
EPEC is known to have high rates of co-infection with other pathogens in children (157), 
the extensive faecal pathogen testing conducted by SCL (for a list of pathogens tested for 
by the Dunedin branch of SCL, refer to Table 6) is consistent with EPEC being the likely 
causative agent of diarrhoea in most of these patients. Sorbitol non-fermenting colonies 
were identified on CT-SMAC from 3 of the eae positive samples, which were confirmed 
as E. coli by MALDI-TOF analysis (refer to Figure 6 in the introduction) before being 
sent to ESR for Shiga toxin testing. All 3 samples were recorded as testing negative for 
Shiga toxin by ESR. As most EPEC strains are sorbitol fermenting (43, 74), it is likely 
SCL is sending irrelevant E. coli isolates to ESR in cases of EPEC infection. These 
findings do not render the use of SMAC-based media to detect O157:H7 redundant, but 
the prevalence of EPEC, in conjunction with the rates of sorbitol non-fermenting STEC 
in diarrhoea, suggest that an update of diagnostic algorithms is needed to meet the more 
salient causes of diarrheic disease in New Zealand. An important consideration for future 
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studies is the bundle forming pili (bfp), encoded by the bfpA gene (194). The bfp is an 
accessory, aggregative colony-forming attachment factor in EPEC and commonly used 
to differentiate ‘typical’ from ‘atypical’ subsets of EPEC (43, 161). Typical EPEC was 
considered the leading cause of diarrhoea in previous decades, but recent data suggests 
atypical EPEC may now be more prevalent in the developed and developed world (161), 
with reports of outbreaks and endemic disease in both (195, 196). 
There were too few faecal calprotectin samples (n = 26) to draw a meaningful comparison 
of the rate of EPEC in these samples with that of regular diarrhoeic specimens (p = 
0.298827; 95% CI). Calprotectin is a neutrophil cytosolic protein released at increased 
concentrations during active bowel inflammation, and is one of the primary markers used 
to discriminate IBD from irritable bowel syndrome (197). The faecal calprotectin 
samples were investigated as severe STEC infection can mimic IBD clinically (27), and 
faecal calprotectin levels may become elevated in infection with EHEC (15). The 
diagnostic algorithm for IBD at SCL involves an immunochromatographic screening 
assay (CERTEST Biotec Calprotectin). Samples suspected of IBD that tested positive 
with this test were confirmed with a quantitative test that detected faecal calprotectin 
levels of >50 μg/g faeces. The two eae+ samples tested negative by the quantitative test. 
This indicates EPEC may have had some minor role in raising the calprotectin levels, but 
it is difficult to surmise more of the role of this pathogen in these patients.  
3.4.8 PVPP column testing 
Of the 522 samples assayed with the multiplex PCR, 95 samples showed either very low 
levels of amplification (Ct over 38 cycles) or no amplification of uidA whatsoever, 
possibly reflecting the effect of an inhibitory compound not alleviated by the pre-
enrichment dilution or Chelex (198). The promotional material for perfeCTaTM 
ToughMix stated the qPCR mix to be resistant to the inhibitory effects of polyphenols, 
humic acids, haemoglobin, haematin, and polysaccharides. Chelex, with affinities to 
chelating Cu2+, Zn2+, Ni2+, Cd2+, Pb2+ and Fe2+ ions, was reasoned to have a 
complementary effect in removing inhibitory heavy metals from samples (124, 140). The 
PVPP, BSA and plasmid experiments were conducted to prospectively identify post-
extraction techniques that could remove putative inhibitors. PVPP spin columns were 
initially investigated as they were demonstrated to be effective in removing humic and 
phenolic compounds from soil and bovine faeces and were available for purchase 
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separate to DNA isolation kits (116, 199, 200). Humic acids and polyphenols were 
considered as candidate inhibitors that might have avoided elimination due to varying 
amounts in human faeces (as derivatives of degraded plant matter) (124, 200) and the 
variable water solubility of humic acids (199). Preliminary testing with PVPP spin 
columns indicated that amplification within a significant proportion of the faecal samples 
could be remedied. However, the amplification of only a small number of faecal samples 
was improved when PVPP processing was applied to the remainder of samples showing 
poor amplification. A few instances of a slight decrease in DNA yield were observed 
after PVPP processing, consistent with the findings of similar studies conducted with 
bovine faeces and soil (124, 199). Although BSA is recommended in several PCR studies 
to counteract the inhibitory effects of lactoferrin and haemoglobin, as may be 
encountered in faecal samples with occult blood (88, 124, 198, 201), the addition of BSA 
resulted in no significant improvement in amplification. It is likely that the addition of 
BSA is redundant; the Fe2+ chelating properties of Chelex would assist in removing iron 
containing compounds (140).  
Subsequent testing of specimens that remained negative with an internal amplification 
probe revealed that the lack of uidA was not as a result of active inhibition, and that PVPP 
had no significant effect in improving DNA yield. The decision to assess diarrhoeic stools 
may have helped in this regard; diarrhoeic stools are postulated to have less potentially 
inhibitory anaerobic and dietary material as a result of the shortened colonic transit time 
(202). The most plausible explanation for the lack of amplification in the absence of PCR 
inhibition is that E. coli in those samples were either absent or the number was below the 
limit of detection of the multiplex even after the 3 hour TSB pre-enrichment. E. coli are 
recognised to be a small and sometimes undetectable fraction of enteric flora (111, 203), 
but the significance of the lack of uidA amplification is difficult to determine as there are 
few published measurements of E. coli CFU g-1 faeces ranges. Bailey et al notes several 
studies of healthy subjects where Enterobacteriaceae and E. coli CFU counts range from 
1 x 104 to 1 x 109 CFU g-1 of faeces (203), while London et al noted 28% of tested faecal 
samples had <103 E. coli CFU g-1 in plate culturing (204). As seen in the stationary-phase 
experiments, stationary-phase, cold-stressed STEC growth rates in faecal samples were 
not greatly hindered. It is possible that E. coli in some naturally infected faeces do not 
share the growth characteristics of the spike model due the action of bacterial colicins or 
other enteric stressors (81, 145, 155, 205-207). Antibiotic regimens of the patients 
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involved in the study remain confidential, and so the role of antibiotic suppression of E. 
coli growth for any samples remains a point of speculation. It is also possible that E. coli 
strains may be become ‘conditioned’ to survival within faecal matrices. Ibarra et al (30), 
describes an enhanced pathogenicity among EHEC strains isolated from faecal 
specimens compared to their immediate parent strain (208); it is not unreasonable to 
suppose that similar conditioning may result in an adaptive stunted growth of STEC in 
short-phase culture, but further experimentation would be necessary to support this 
theory.  
Any investigation of the properties of the E. coli strains supposedly missed by the 
enrichment-extraction method chosen for the project would likely require a comparison 
with a more sensitive method. A comparative study recently conducted by Wagner et al 
(136) highlighted a number of potentially more sensitive (albeit more expensive) faecal 
DNA extraction kits that could be used to recover ‘missed’ strains, perhaps combined 
with a longer pre-enrichment phase. As Chelex is only a metal-chelating resin, biases 
introduced by proteins and other particles limit the accuracy of spectrophotometric 
quantification or standardisation of the DNA of Chelex-extracted samples (131). Qubit-
based fluorometric DNA quantification of faecal DNA is one avenue that could be 
explored if future experimentation with Chelex is pursued (209). E. coli markers other 
than uidA such as wecA could also be explored (62), although the failure of this assay is 
unlikely as all E. coli controls to date have performed as expected. Ultimately, there could 
be many reasons for the lack of uidA amplification seen, but these proposed experiments 
could help to resolve details.  
3.4.9 LAMP based detection of O157 serotypes and ESR serotyping 
The LAMP analysis of the stx positive samples indicated that the primers used were 
capable of delineating O157 serogroups of STEC from non-O157 serogroups. The 
LAMP results were later verified by molecular serotyping performed by ESR. The results 
indicate a basic LAMP assay could be incorporated as an inexpensive part of a diagnostic 
algorithm (90), or incorporated as a confirmatory test of O157 serotypes in multiplex-
based screening. 
The serotyping results returned by ESR specified that all but two of the stx+ samples 
could not be serotyped. This is in contrast to international STEC trends; most isolates of 
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non-O157 E. coli that are associated with human disease belong to the serogroups O26, 
O103, O145, O111, O45 or O121 as would be detected by the ESR wzx serotyping assays 
(21, 32, 36, 169, 210). Comprehensive serotyping of the non-O157 stx+ samples was not 
possible as the samples were retained in extracted form, and few serotype-specific 
primers for other the more obscure serotypes have been developed. A study of stool 
specimens at Dunedin Hospital in 2001 by Brooks et al revealed a variety of unusual 
non-O157, non-‘big six’ serotypes, with no clearly dominant serotype (211), and a study 
by the same author in 1997 encountered some overlap in serotypes recovered from meats 
sourced from Dunedin retail outlets (212). Similarly, a study of clinical specimens 
sourced from medical laboratories and the Enteric Laboratory at ESR by Jaros et al (72), 
found a host of non-O157 stx+ serogroups, many of which are also isolated from New 
Zealand sheep and cattle (70). Notably, the genomic DNA profiles of O84:H- isolates 
derived from New Zealand cattle were determined to be sufficiently similar to that of 
clinical isolates by PFGE analysis as to infer medical significance (71). It is likely that 
the non-O157 specimens extracted in this project belong to a combination of the 
serotypes listed in these studies. An Australian analysis of state and national STEC 
infections by Vally et al (10), albeit likely influenced by SMAC-based reporting (213), 
reported 58% of serotyped STEC infections being of the serogroup O157, with a further 
13.7% of serogroup O111 and 11.1% of serogroup O26. 
The two samples found to be positive for the serogroups O157 and O103 are an intriguing 
find. While co-infections involving two or more STEC serotypes are not unusual (214), 
two instances of infection with the same two STEC serogroups are somewhat suggestive 
of a common source infection or transmission event. The inability of the ESR fliC assay 
to determine a flagellar (H) antigen in these two samples is also surprising; this suggests 
that the O157 strain seen in these samples may belong to one of the rarer and generally 
less pathogenic O157 serotypes, such as O157:H6, O157:H39, O157:H45, or O157:H16, 
among others (215, 216). These non-H7 O157 types are noted to have high rates of 
sorbitol fermentation (217). Another plausible explanation, and one that fits well with 
the samples being severe enough to warrant clinical attention and yet remaining 
undetected by conventional methods, is that the H antigen in the observed O157 strains 
is untypeable, and therefore possibly the O157:H- serotype. O157:H-, or O157:HNM 
(non-motile) is a unique STEC serotype first isolated in a 1988 outbreak in Germany 
(218, 219). Approximately 10% of O157 infections and HUS cases are caused by 
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O157:H- strains in continental Europe (75, 210, 220), and the serotype is recognised to 
have high rates of tellurite sensitivity and sorbitol-fermentation (75, 98, 210, 221). As a 
result, this serotype is inhibited by tellurite used in CT-SMAC and indistinguishable from 
commensal enteric bacteria on unsupplemented SMAC (75, 98, 221, 222). All European 
isolates of O157:H- strains express high levels of Stx2 toxin (210, 223), and the clinical 
profile of the serotype is not considered to differ significantly from O157:H7 in paediatric 
patients (220). A third possibility that cannot be dismissed, and one that also applies to 
the other stx+ and eae+ samples, is that other untyped stx- or eae-carrying E. coli strains 
exist within these samples, and that multiple strains may be present and in possession of 
combinations of the detected genes.  One of the limitations of the multiplex assay used 
in this project is that the origin of the virulence factors cannot be determined in cases of 
STEC co-infection, so it is impossible to determine whether the stx1 and eae detected in 
the two O157:H- samples were derived from the O157:H- strain or the co-residing O103 
strain, or a third party E. coli. Ultimately, this is a shortcoming of the use of multiplex 
qRT-PCR; live isolates of these samples would be required to determine more detailed 
serological information and comprehensively establish the origin of each virulence factor 
in each sample. 
One point of consideration for future studies or in-depth profiling of the existing 
extracted stx2+ samples are stx2 subvariants. The stx2 assay used in the project multiplex 
does not discriminate between the stx2 subvariants stx2, stx2c and stxd, which are noted 
to have differing associations to severe disease and progression to HUS (34, 224). A finer 
characterisation of stx2+ STEC strains could be undertaken with the use of stx2 
subvariant-specific primer sets (34, 53, 210, 224). The use of SK-LP primers to 
characterise intimin subvariants could also be employed in future studies (218). 
Determination of virulence profiles of O157:H- extracts may provide information 
concerning the geographical origin (European or Australian) of these organisms. A larger 
survey than the one reported here would establish whether the O157:H7 or O157:H- 
serotype was dominant in diarrhoeic samples received by SCL at Dunedin Hospital. 
3.5.0 Conclusions and future considerations 
A multiplex qRT-PCR assay capable of detecting marker genes for STEC and EPEC was 
successfully adapted for use in high-throughput diagnostic practice. The protocol was 
developed to include a 3 hour non-selective TSB pre-enrichment to boost the sensitivity 
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of STEC and EPEC detection and use of Chelex-100 resin as an inexpensive and labour-
efficient DNA extraction method. It was found that the protocol could not be adapted to 
derive meaningful quantitative information on the levels of STEC or EPEC bacteria in 
infected stool samples. The pre-enrichment was demonstrated to boost sensitivity to 2 x 
102 CFU per g faeces in faecal STEC growth models. The prevalence of STEC and EPEC 
among diarrhoeic stools sourced from SCL, Dunedin Hospital was determined to be 
1.53% and 4.41% (95% CI) respectively. STEC were found in several faecal samples set 
aside for H. pylori testing, and trends indicate a significantly higher rate of STEC 
infection may be found among these sample compared to the rest of the diarrhoeic stools 
in a larger survey (Fisher Exact test (p = 0.063; 95% CI). The multiplex assay was also 
used to screen samples set aside for IBD testing, and although no statistically significant 
results were found, there was evidence implicating EPEC in raising faecal calprotectin 
levels in some patients and contributing to redundant isolates being sent to ESR. Testing 
of LAMP-based amplification revealed some applicability to diagnostic practice in being 
able to discriminate O157 serogroups from non-O157s. Commercial molecular 
diagnostic systems, such as the real-time Enteric Bio Gasto 2 (SeroSep Ltd, Annacotty, 
Ireland) include stx1 and stx2 testing panels (225). However, these systems are not 
designed to detect intimin, which is a marker for EPEC, and a marker of increased 
virulence for STEC. The qRT-PCR assay developed in this project was able to detect the 
gene markers for both STEC and EPEC, the latter being more abundant in the diarrhoeal 
stool samples tested in this project. 
A number of directions were considered for future research into the role of STEC and 
EPEC in human health in New Zealand. Further investigation into the prevalence of 
STEC and EPEC would benefit from study in the months of peak infection in New 
Zealand, likely including a culture-based component so that more extensive serotyping 
information can be derived from live isolates. A culture based component to testing 
would also help to determine which strains are dead or non-viable but detectable by PCR 
(150, 151). If Chelex-based DNA extraction is to be pursued for faecal samples in 
diagnostic practice, protocol modifications and the use of Qubit could be implemented 
improve extraction consistency (141, 209, 226, 227), and acid-pretreatment could be 
explored to improve assay specificity without compromising the effects of short pre-
enrichments (105). A more detailed examination of the stx2 and intimin subtypes and 
other virulence factors in the existing extracted samples or other surveys could provide 
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closer links to exact pathologies seen in the literature (34, 55, 179, 210, 224). Ultimately, 
the prevalences of STEC and EPEC uncovered by this project are indicative of an 
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Standard Operating Procedure for the use of STEC and faecal samples  
1. Purpose:  
The intent of this study is to determine the prevalence of non-O157 serotypes of Shiga-
toxigenic E. coli (STEC) in diarrhoeal faecal samples collected by Southern Community 
Laboratories.   
The experimental procedure is expected to comprise liquid media culturing and DNA 
amplification of selected STEC strains as a preface to testing faecal samples of unknown 
pathogenicity.  
  
2. Hazards, Exposures, Controls, and Containment:  
The primary hazards in initial testing will be E. coli strain serotypes O111, O91NM, O130H11, 
O84  
(O111 obtained from Brooks lab, Shiga toxin-carrying O91NM, O84 and O130:H11 obtained 
from ESR). These pathogens may be transmitted through ingestion or contact with the mucous 
membranes of the mouth, nose and eyes, and are recognised to be further spread through the 
contamination of work surfaces and fomites. Symptoms of exposure to E. coli range from mild, 
watery diarrhoea to abdominal cramping and bloody diarrhoea. If you contract these 
symptoms, notify your supervisor immediately.   
Subsequent testing will involve faecal samples likely to contain a variety of gastrointestinal 
pathogens, most notably Hepatitis A, Norovirus, Cryptosporidium, and other pathogenic 
strains of E. coli. The use of faecal samples represents a significant health risk as some faecal 
pathogens (particularly Norovirus) have extremely low infectious doses, can be spread 
through inhalation of aerosolised emesis, and are resistant to some forms of disinfection.  
Refer to Table 1 for the principle hazards of faecal samples.  
  
All laboratory work with live E. coli strains O91NM, O130H11, and untreated faecal samples 
will be undertaken in a Class II biosafety cabinet. The use of racks and other holders is 
recommended to limit spills inside the cabinet. Enteropathogenic E. coli O111 is shiga-toxin 
negative and may be handled on the bench, providing appropriate PPE is used. Any work with 
O111 likely to generate aerosols, (eg. vortexing) must be performed inside the cabinet.  
Barrier tips will be used for pipetting work with E. coli strains and faecal samples.  
All laboratory workers must wear appropriate Personal Protective Equipment (PPE; lab coats 
and disposable gloves). Double-gloving and the use of disposable lab coats or sleeves are 
recommended for the processing of faecal samples. Change/decontaminate outer gloves and 
disposable coats/sleeves frequently and in the event of spills on gloves/sleeves to avoid 
contamination of lab surfaces. Decontaminate culture vessels, secondary containers and other 
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equipment before removing from Class II cabinets, especially the interior of pipettor barrels. 
Disposable PPE must be discarded into marked biohazard bags and lab coats must be removed 
before leaving the lab. Outer gloves and disposable sleeves should ideally be removed and 
disposed of into discard containers inside the cabinet following the decontamination of all 
equipment and surfaces. Be sure to change gloves or sleeves if you suspect they are 
contaminated.   
Properly extracted DNA from the sample E. coli and faecal samples poses negligible 
transmission risk and so does not require use of the biosafety cabinet, but PPE is still 
recommended.   
Wash hands thoroughly upon leaving the lab.  
Where possible, but particularly in the event samples need to be transported outside the 
laboratory, samples must be contained in sealable secondary containers (click-clacks). Include 
absorbent material in the secondary containers to soak up any spilled material (change as 
necessary).  
  
3. Experimental procedures  
The E. coli serotypes and faecal samples will be cultured, incubated and chilled with media 
designed to amplify E. coli. The use of secondary containers for liquid/faecal sample 
incubation/refrigeration is recommended, although parafilm wrapping will be sufficient for 
the refrigeration/incubation of plate cultures. Cultures and containers with potentially 
infectious organisms will be labelled with appropriate biohazard stickers/laminated labels.  
  
4. Inactivation, Decontamination, Waste Treatment and Disposal  
All work surfaces including the biohazard cabinet must decontaminated before and after use 
of live species and faecal samples, at the end of a working day, and immediately after any 
spills. A 1:10 dilution of household bleach (made fresh daily) with 5-10 min contact time is the 
preferred disinfectant, though others may be useable. Hydrogen peroxide (for the inactivation 
of Cryptosporidium) is itself partially inactivated by bleach, so an excess of bleach must be 
used following hydrogen peroxide treatment of spills, and the use of hydrogen peroxide is 
only recommended in the event of a spill of a faecal sample. It is not necessary to clean the 
cabinet surfaces with hydrogen peroxide as the cabinet UV light is sufficient in killing 
Cryptosporidium (see Table 1). As bleach is corrosive, a final ethanol wipe down must be 
performed to preserve the integrity of the metal surfaces in the cabinet.  
Outer gloves and sleeves must be removed/changed after work in the cabinet.   
Must take care to avoid contamination of pipettors and other equipment inside the cabinet. 
All used equipment and unused samples must be decontaminated or disposed of in red 
biohazard bags.  
  
5. Spills and Emergency Exposure Procedures  
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In the event of spills outside the cabinet, cover any spills of live bacteria with paper towels. 
Saturate towels with 1:10 dilution of household bleach (made fresh daily) and allow 5-10 min 
contact time. Wipe up area and discard towels in red biohazard bag. Repeat disinfection 
procedure until surface is clean. Wash any exposed skin thoroughly with soap and water. 
Perform first aid if necessary.  Along with supervisor, complete accident report form.  
  
  Table 1: Most virulent, transmissible faecal pathogens and their treatments  
  Infectious 
Dose  
Transmission  Incubation  
Period,  
Duration  










12-48h, up to 
60h.  
Acute onset projectile 
vomiting, non-bloody 
diarrhoea, abdominal 
cramps. Self-limiting.  
1000-5000ppm 
chlorine bleach  
1, 2  











diarrhoea, dark urine,  
jaundice, fever, 
headache, abdominal 
pain. Self limiting.  
1:100 bleach  3, 4  
Cryptosporidium sp.  ~30 oocysts, 
theoretically 
may be as 
low as 1  
Fecal-oral, either 
directly or via 
fomites. Respiratory 
infection possible 
but rare.  
5-9 days, 11-13 
days.  












surfaces. *  
5  




or via fomites.  
2-10 days (2-3 




May have fever, 
vomiting. May 








* At current wattage (740mW/m2), the biosafety cabinet UV light can inactivate >90% of 
Cryptosporidium oocysts on cabinet surfaces within 90 seconds, based upon a lethal dosage 
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This document is a copy of a clarification requested by the University of Otago’s Human 
Ethics Committee regarding privacy concerns about the project, and contains relevant 
supplementary legal and ethical information. Written confirmation to access of faecal 
samples by SCL (as mentioned in this document) is not included, but was obtained prior 
to the Committee’s approval (and a requisite of it). 
A copy of the Committee’s approval is provided at the end of this document. 
 
The Committee request comment and clarification on the following: 
1. Are the samples already held by Southern Community Laboratories (SCL), or will they be 
collected in the future. If the former, did the specimen-providing individuals give permission 
for future research to be conducted? If the latter, what grounds are there not to obtain 
informed consent? 
The samples are to be collected by SCL in the future, pending Human Ethics Committee 
approval. Both the Human Tissue Act 2008 and Health Information Privacy Code 1994 
can be seen to provide reasonable grounds to not seek informed consent for the 
purposes of this study, insofar as faeces are noticeably not mentioned as human tissue 
in the Act and no information that could be used to identify the patient will be supplied 
to the researchers in accordance with the Code. 
In the case of the Human Tissue Act 2008, while section 7 (1a and 1b) does define 
human tissue as that being derived from a living individual and which includes human 
cells, no mention of faeces is made in the examples that follow in Section 7, despite 
urine, sputum, mucus and similar body fluids being clearly specified. It should be made 
clear at this point that the test to be performed is specific to E. coli and has no capacity 
to reveal information about the patient beyond the presence of Shiga-toxigenic E. coli 
bacteria in the stool sample. 
Informed consent for the use of faecal culture inoculants is deemed unnecessary as 
defined by the Health Information Privacy Code 1994, Rule 11 (2) which states 
compliance with Rule 11 (1) (b) (that is, informed consent of the individual supplying 
the tissue sample) is not necessary if the information is (as is the case with this study) 
“(i) to be used in a form in which the individual concerned is not identified; or (ii) is to 
be used for statistical purposes and will not be published in a form that could reasonably 
be expected to identify the individual concerned; or (iii) is to be used for research 
purposes (for which approval by an ethics committee, if required, has been given) and 
will not be published in a form that could reasonably be expected to identify the 
individual concerned”. Any of the above clauses could be reasonably applied to the use 
of personal information in this study, although it is to be made clear that no information 
that can be used to identify patients supplying faecal inoculants will be released by SCL 
to researchers undertaking the project. As the study is intended to be a retrospective 
prevalence study of Shiga-toxigenic E. coli (STEC) and not expected to be of direct 
therapeutic benefit to the patients involved (detection of STEC is unlikely to be 
influential in the course of treatment, as the disease is usually of short duration and 
self-limiting), informed consent is deemed to be of little benefit. It should also be noted 
that, as SCL has a large and disparate sample catchment area, it is expected that seeking 
informed consent for the use of any and all samples is not practicable and that any 
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resulting shortcomings in patient response will have a deleterious effect on the 
relevance of this project as a prevalence study.  
 
2. The answer in Section 4 of the form notes that there will be no access to identifiable 
health information. Presumably the stool samples will be initially identified at SCL. Please 
indicate what process will be used to de-identify the specimens. 
Samples will be used to inoculate enrichment broths which will only be labelled with 
patient status (in/out patient), age (whether ≤12 years or older only), and a unique ID 
assigned by SCL (not a personal identifier eg NHI number, but a special code 
determined by SCL for this research purpose). The intent is that the specimens 
received by the university are not the faecal samples themselves complete with 
personal information but derivative cultures of faecal materials with personal 
identifiers removed. 
 
3. The Committee request comment on how abnormal results will be dealt with and how 
this will be communicated to the individual whose sample has been tested; if you are 
proposing to not inform individuals then the committee request a justification for not 
doing so. 
The test used is a molecular-based assay specifically designed to only detect the 
presence of STEC and has no capacity to determine any other underlying health 
problems or causes of diarrhoea. Owing to the large number of specimens that are 
expected to be processed, the amount of time that this will take, and the cost-
efficiency of testing individual samples, it is expected that for the purposes of this 
study the specimens will be analysed in large batches following processing, and that 
this will likely take place after any positive result will be of therapeutic value to health 
workers or the patients from which the samples were derived. Added to this, as the 
test in its current state cannot distinguish between the exclusively pathogenic 
serotypes of STEC and those with more tenuous links to human disease, it cannot be 




4. In Section 6, “N/A” is the response to the requirement for authorisation by the Health 
agency. If the health agency is providing the specimens it is authorising their use and the 
University requires formal authorisation. 
A notice of formal authorisation for the project researchers to access faecal inoculants 


























(Pertinent section of SHDB Tikaka Best Practice Document)   
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Appendix 5  
Nanodrop data 
  
The following table contains the spectroscopy readings obtained from the NanoDrop 
(DNA-50 function with NanoDrop 1000, v3.7.1, Thermo-Fisher Scientific) for the DNA 
extraction comparison experiment. The boiling, Chelex and Phenol-Chloroform readings 
were obtained from 1 mL (each) of O111:K88:H- culture, whereas 0.2 mL was processed 
with the PrepMan. The extracted samples were diluted (based on the average of the 
triplicate reads shown here) to account for this difference in volume before comparison 
of their relative amplification of the uidA gene by RT-PCR.  
 
The culture sample processed by boiling extraction appears to have the greatest DNA 
concentration, but this method was found to have the lowest yield in the subsequent PCR 
assay. Based on the concurrent gel photo (see Figure 19(a)), it appears that much of the 
DNA that was extracted by the boiling method was highly fragmented, and so it is likely 
the NanoDrop concentration shown is comprised of poor quality DNA. The 260/280 ratio 
indicates that the reading is not influenced by protein carryover from the extraction of 
the broth, although it is possible other particles in solution may have contributed to 
concentration bias1. The lower concentration of PrepMan as extracted likely contributed 
to its faintness on the gel, although this method also showed significantly more 
fragmentation than that of the Chelex method.
                                                          
1 Gallagher SR, Desjardins PR. Quantitation of DNA and RNA with absorption and fluorescence 
spectroscopy. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Struhl K, editors. Current 
protocols in human genetics. 4. New York: John Wiley and Sons, Inc.; 2007. 




















stx-bearing E. coli strain genome sizes and GC content (NCBI database) 
NCBI E. coli strains (completed sequences) Genome Size (Mb) GC% NCBI chromosome FASTA seq ref no. 
O103:H2 str. 12009 5.52486 50.68 NC_013353.1 
O111:H- str. 11128 5.76608 50.42 NC_013364.1 
O157:H7 str. EC4115 5.70417 50.39 NC_011353.1 
O157:H7 str. TW14359 5.62274 50.46 NC_013008.1 
O26:H11 str. 11368 5.85553 50.66 NC_013361.1 
Xuzhou21 5.51674 50.38 NC_017906.1 
O145:H28 str. RM13514 5.73729 50.67 NZ_CP006027.1 
O145:H28 str. RM13516 5.55901 50.59 NZ_CP006262.1 
O157:H7 str. SS17 5.65594 50.38 NZ_CP008805.1 
O157:H7 str. EDL933 5.62052 50.35 AE005174.2 
O157:H7 str. Sakai RIMD 0509952 5.59448 50.45 NC_002695.1 
UMNF18 5.6353 50.58 NZ_AGTD01000001.1 
O104:H4 str. 2011C-3493 5.43741 50.63 NC_018658.1 
O104:H4 str. 2009EL-2050 5.43817 50.54 NC_018650.1 
O104:H4 str. 2009EL-2071 5.38971 50.65 NC_018661.1 
O145:H28 str. RM12761 5.55901 50.59 NZ_CP007133.1 
O145:H28 str. RM12581 5.73729 50.67 NZ_CP007136.1 
Mean values 5.609073529 50.53  





Non stx-bearing E. coli genomes 
  
 
Non Stx-bearing E. coli strain genome sizes and GC content 
Non STEC strains Genome Size (Mb) GC% 
Escherichia coli str. K-12 substr. MG1655 4.64165 50.8 
Escherichia coli CFT073 5.23143 50.5 
Escherichia coli BL21(DE3) 4.55895 50.8 
Escherichia coli SE11 5.15563 50.75 
Escherichia coli SE15 4.83968 50.71 
Escherichia coli UTI89 5.17997 50.61 
Escherichia coli 536 4.93892 50.5 
Escherichia coli APEC O1 5.49765 50.29 
Escherichia coli E24377A 5.24929 50.54 
Escherichia coli HS 4.64354 50.8 
Escherichia coli B str. REL606 4.62981 50.8 
Escherichia coli ATCC 8739 4.74622 50.9 
Escherichia coli str. K-12 substr. DH10B 4.68614 50.8 
Escherichia coli SMS-3-5 5.21538 50.5 
Escherichia coli BW2952 4.57816 50.8 
Escherichia coli DH1 4.57094 50.8 
Escherichia coli 'BL21-Gold(DE3)pLysS AG' 4.57094 50.8 
Escherichia coli O55:H7 str. CB9615 5.45235 50.48 
Escherichia coli IHE3034 5.10838 50.7 
Escherichia coli 55989 5.15486 50.7 
Escherichia coli IAI1 4.70056 50.8 
Escherichia coli S88 5.16612 50.66 
Escherichia coli O127:H6 str. E2348/69 5.06968 50.55 
Escherichia coli 042 5.35532 50.58 
Escherichia coli KO11FL 5.02932 50.78 
Escherichia coli ABU 83972 5.13296 50.6 
Escherichia coli UM146 5.10756 50.61 
Escherichia coli W 5.00886 50.78 
Escherichia coli ETEC H10407 5.32589 50.73 
Mean values 4.98435 50.68 
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